[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ffm5ZbcPrtDU8dQLoYN-id-sTSzQaJ1lEd_XJnj5A1tc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Karolinska Institutet",[4],1106,false,300,48,31503754,36,964,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Depression",26,{"name":18,"count":19},"Anxiety",20,{"name":21,"count":19},"Stroke",{"name":23,"count":24},"Insomnia",15,{"name":26,"count":24},"Anxiety Disorders",{"name":28,"count":29},"Atrial Fibrillation",14,{"name":31,"count":29},"Obesity",{"name":33,"count":34},"Prostate Cancer",13,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT00555607","Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease","2005-04","prednisolone",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04065009","The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer","2024-01-10","Ropivacaine",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT02647827","Acupuncture or Metformin for Insulin Resistance in Women With PCOS","2025-06","Metformin",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05720065","Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A","2025-06-30","Botulinum toxin type A",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06025916","Postpartum Hemorrhage Reduction With Oral Tranexamic Acid: a Clinical Trial","2025-12","Tranexamic acid",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT03832712","The Swedish Essential Tremor (SWEET) Trial","2026-01-30","Best Medical Treatment",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07606378","Efficacy of PRP Injections in Reducing Pain for Myogenous TMD Patients","2026-08-30","Saline",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05501483","Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes","2026-09-01","Pioglitazone 45 mg",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT03903835","ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","2026-12","Enzalutamide Oral",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT03720262","Prevention of Hernia After Loop Ileostomy Reversal","2026-12-31","Mesh reinforcement",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,125,143,165,192,230,267,293,311,333,364,382,400,418,436,454,472,490,508,526,544,596,631,656,683,701,727,745,771,792,822,847,870,888,906,929,951,987,1026,1065,1104,1126,1148,1183,1211,1238,1256,1274,1300,1327,1353,1371,1389,1415,1441,1469,1496,1520,1538,1564,1582,1600,1618,1647,1665,1692,1710,1734,1759,1777,1802,1820,1845,1863,1907,1948,1976,2003,2021,2052,2078,2104,2130,2148,2174,2192,2216,2234,2258,2285,2311,2329,2354,2372,2390,2408,2433,2451,2486,2519,2554,2589,2613,2638,2656,2681,2710,2728,2746,2764,2789,2807,2829,2854,2872,2897,2919,2937,2961,2979,3000,3023,3041,3074,3099,3125,3143,3168,3193,3217,3239,3257,3281,3299,3322,3347,3385,3425,3454,3483,3519,3551,3576,3601,3619,3646,3664,3688,3706,3729,3756,3779,3804,3829,3847,3872,3898,3916,3942,3960,3985,4012,4035,4059,4081,4105,4129,4156,4174,4192,4217,4243,4269,4294,4319,4345,4372,4390,4414,4443,4461,4479,4497,4521],{"intervention":95,"totalTrials":96,"cells":97},"Apixaban",1,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":123},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":100},[],{"trials":106,"activeCount":100},[],{"trials":108,"activeCount":96,"soonestReadout":114},[109],{"nctId":110,"briefTitle":111,"status":112,"phases":113,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"NCT06515730","Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","RECRUITING",[91],"2028-04-08","2028-07-01","2025-04-08",212,[119,120],"Left Ventricular Thrombus","Acute Myocardial Infarction",[95,122],"Warfarin",{"trials":124,"activeCount":100},[],{"intervention":122,"totalTrials":96,"cells":126},{"EARLY_PHASE1":127,"PHASE1":129,"PHASE2":131,"PHASE3":133,"PHASE4":135,"NA":141},{"trials":128,"activeCount":100},[],{"trials":130,"activeCount":100},[],{"trials":132,"activeCount":100},[],{"trials":134,"activeCount":100},[],{"trials":136,"activeCount":96,"soonestReadout":114},[137],{"nctId":110,"briefTitle":111,"status":112,"phases":138,"primaryCompletion":114,"completion":115,"start":116,"enrollment":117,"conditions":139,"interventions":140},[91],[119,120],[95,122],{"trials":142,"activeCount":100},[],{"intervention":60,"totalTrials":96,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":151,"PHASE4":153,"NA":163},{"trials":146,"activeCount":100},[],{"trials":148,"activeCount":100},[],{"trials":150,"activeCount":100},[],{"trials":152,"activeCount":100},[],{"trials":154,"activeCount":96,"soonestReadout":59},[155],{"nctId":57,"briefTitle":58,"status":112,"phases":156,"primaryCompletion":59,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":162},[91],"2026-03","2023-09-27",1000,[161],"PPH",[60],{"trials":164,"activeCount":100},[],{"intervention":166,"totalTrials":96,"cells":167},"Gardasil 9 2 dose regimen",{"EARLY_PHASE1":168,"PHASE1":170,"PHASE2":172,"PHASE3":174,"PHASE4":176,"NA":190},{"trials":169,"activeCount":100},[],{"trials":171,"activeCount":100},[],{"trials":173,"activeCount":100},[],{"trials":175,"activeCount":100},[],{"trials":177,"activeCount":96,"soonestReadout":183},[178],{"nctId":179,"briefTitle":180,"status":181,"phases":182,"primaryCompletion":183,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},"NCT07314307","Vaccine Effectiveness of One Dose of the Nonavalent Human Papillomavirus (HPV) Vaccine Among Young-adult Women in Sweden Among Women Participating in a Clinical Trial of Concomitant HPV Vaccination and Screening","ACTIVE_NOT_RECRUITING",[91],"2027-12-31","2028-12-31","2021-05-03",150000,[188],"Incident HPV16, 18, 31, 33, 45, 52 or 58 Infection",[166],{"trials":191,"activeCount":100},[],{"intervention":193,"totalTrials":194,"cells":195},"Diclofenac",2,{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":213,"NA":228},{"trials":197,"activeCount":100},[],{"trials":199,"activeCount":100},[],{"trials":201,"activeCount":100},[],{"trials":203,"activeCount":96,"soonestReadout":183},[204],{"nctId":205,"briefTitle":206,"status":207,"phases":208,"primaryCompletion":183,"completion":184,"start":209,"enrollment":159,"conditions":210,"interventions":212},"NCT03595150","Diclofenac for Prevention of Post-ERC Pancreatitis","NOT_YET_RECRUITING",[89,90],"2026-01-01",[211],"Common Bile Duct Diseases",[193],{"trials":214,"activeCount":100},[215],{"nctId":216,"briefTitle":217,"status":218,"phases":219,"primaryCompletion":220,"completion":221,"start":222,"enrollment":100,"conditions":223,"interventions":226},"NCT01190722","A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain","WITHDRAWN",[91],"2010-12-11","2010-12-12","2010-11-10",[224,225],"Hallux Valgus","Postoperative Pain",[227,193],"etoricoxib",{"trials":229,"activeCount":100},[],{"intervention":231,"totalTrials":194,"cells":232},"Saline Solution",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":263,"NA":265},{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":100},[],{"trials":240,"activeCount":96,"soonestReadout":44},[241,249],{"nctId":42,"briefTitle":43,"status":181,"phases":242,"primaryCompletion":44,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":248},[90],"2028-08-26","2020-08-26",220,[247],"Advanced Ovarian Cancer",[45,231],{"nctId":250,"briefTitle":251,"status":252,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":260},"NCT02619149","Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis","COMPLETED",[90],"2017-12","2018-01","2009-03",100,[259],"Cholecystitis, Acute",[261,262],"Piperacillin-tazobactam combination product","Saline solution",{"trials":264,"activeCount":100},[],{"trials":266,"activeCount":100},[],{"intervention":268,"totalTrials":96,"cells":269},"Individual dose of tamoxifen",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":289,"NA":291},{"trials":271,"activeCount":100},[],{"trials":273,"activeCount":100},[],{"trials":275,"activeCount":100},[],{"trials":277,"activeCount":96,"soonestReadout":282},[278],{"nctId":279,"briefTitle":280,"status":207,"phases":281,"primaryCompletion":282,"completion":282,"start":157,"enrollment":283,"conditions":284,"interventions":287},"NCT07502820","The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER",[90],"2036-08",1100,[285,286],"Breast Cancer","Adjuvant Drug Therapy",[268,288],"Standard adjuvant therapy of tamoxifen",{"trials":290,"activeCount":100},[],{"trials":292,"activeCount":100},[],{"intervention":288,"totalTrials":96,"cells":294},{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":307,"NA":309},{"trials":296,"activeCount":100},[],{"trials":298,"activeCount":100},[],{"trials":300,"activeCount":100},[],{"trials":302,"activeCount":96,"soonestReadout":282},[303],{"nctId":279,"briefTitle":280,"status":207,"phases":304,"primaryCompletion":282,"completion":282,"start":157,"enrollment":283,"conditions":305,"interventions":306},[90],[285,286],[268,288],{"trials":308,"activeCount":100},[],{"trials":310,"activeCount":100},[],{"intervention":85,"totalTrials":96,"cells":312},{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":329,"NA":331},{"trials":314,"activeCount":100},[],{"trials":316,"activeCount":100},[],{"trials":318,"activeCount":100},[],{"trials":320,"activeCount":96,"soonestReadout":84},[321],{"nctId":82,"briefTitle":83,"status":112,"phases":322,"primaryCompletion":84,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},[89,90],"2029-12-31","2018-03-01",208,[327],"Loop Ileostomy",[85],{"trials":330,"activeCount":100},[],{"trials":332,"activeCount":100},[],{"intervention":80,"totalTrials":96,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":360,"NA":362},{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":100},[],{"trials":342,"activeCount":96,"soonestReadout":79},[343],{"nctId":77,"briefTitle":78,"status":112,"phases":344,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":347,"interventions":350},[90],"2019-02-01",750,[348,349],"Metastatic Castration-resistant Prostate Cancer (mCRPC)","Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)",[80,351,352,353,354,355,356,357,358,359],"Abiraterone Oral","Carboplatin","Cabazitaxel 60 mg Solution for","Docetaxel Injectable Solution","Radium Chloride Ra-223","Niraparib plus Abiraterone acetate plus Prednisone","Capivasertib plus Docetaxel","Apalutamide","Darolutamide",{"trials":361,"activeCount":100},[],{"trials":363,"activeCount":100},[],{"intervention":351,"totalTrials":96,"cells":365},{"EARLY_PHASE1":366,"PHASE1":368,"PHASE2":370,"PHASE3":372,"PHASE4":378,"NA":380},{"trials":367,"activeCount":100},[],{"trials":369,"activeCount":100},[],{"trials":371,"activeCount":100},[],{"trials":373,"activeCount":96,"soonestReadout":79},[374],{"nctId":77,"briefTitle":78,"status":112,"phases":375,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":376,"interventions":377},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":379,"activeCount":100},[],{"trials":381,"activeCount":100},[],{"intervention":352,"totalTrials":96,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":396,"NA":398},{"trials":385,"activeCount":100},[],{"trials":387,"activeCount":100},[],{"trials":389,"activeCount":100},[],{"trials":391,"activeCount":96,"soonestReadout":79},[392],{"nctId":77,"briefTitle":78,"status":112,"phases":393,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":394,"interventions":395},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":397,"activeCount":100},[],{"trials":399,"activeCount":100},[],{"intervention":353,"totalTrials":96,"cells":401},{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":414,"NA":416},{"trials":403,"activeCount":100},[],{"trials":405,"activeCount":100},[],{"trials":407,"activeCount":100},[],{"trials":409,"activeCount":96,"soonestReadout":79},[410],{"nctId":77,"briefTitle":78,"status":112,"phases":411,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":412,"interventions":413},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":415,"activeCount":100},[],{"trials":417,"activeCount":100},[],{"intervention":354,"totalTrials":96,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":432,"NA":434},{"trials":421,"activeCount":100},[],{"trials":423,"activeCount":100},[],{"trials":425,"activeCount":100},[],{"trials":427,"activeCount":96,"soonestReadout":79},[428],{"nctId":77,"briefTitle":78,"status":112,"phases":429,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":430,"interventions":431},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":433,"activeCount":100},[],{"trials":435,"activeCount":100},[],{"intervention":355,"totalTrials":96,"cells":437},{"EARLY_PHASE1":438,"PHASE1":440,"PHASE2":442,"PHASE3":444,"PHASE4":450,"NA":452},{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":100},[],{"trials":443,"activeCount":100},[],{"trials":445,"activeCount":96,"soonestReadout":79},[446],{"nctId":77,"briefTitle":78,"status":112,"phases":447,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":448,"interventions":449},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":451,"activeCount":100},[],{"trials":453,"activeCount":100},[],{"intervention":356,"totalTrials":96,"cells":455},{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":462,"PHASE4":468,"NA":470},{"trials":457,"activeCount":100},[],{"trials":459,"activeCount":100},[],{"trials":461,"activeCount":100},[],{"trials":463,"activeCount":96,"soonestReadout":79},[464],{"nctId":77,"briefTitle":78,"status":112,"phases":465,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":466,"interventions":467},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":469,"activeCount":100},[],{"trials":471,"activeCount":100},[],{"intervention":357,"totalTrials":96,"cells":473},{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":486,"NA":488},{"trials":475,"activeCount":100},[],{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":96,"soonestReadout":79},[482],{"nctId":77,"briefTitle":78,"status":112,"phases":483,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":484,"interventions":485},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":487,"activeCount":100},[],{"trials":489,"activeCount":100},[],{"intervention":358,"totalTrials":96,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":504,"NA":506},{"trials":493,"activeCount":100},[],{"trials":495,"activeCount":100},[],{"trials":497,"activeCount":100},[],{"trials":499,"activeCount":96,"soonestReadout":79},[500],{"nctId":77,"briefTitle":78,"status":112,"phases":501,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":502,"interventions":503},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":505,"activeCount":100},[],{"trials":507,"activeCount":100},[],{"intervention":359,"totalTrials":96,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":522,"NA":524},{"trials":511,"activeCount":100},[],{"trials":513,"activeCount":100},[],{"trials":515,"activeCount":100},[],{"trials":517,"activeCount":96,"soonestReadout":79},[518],{"nctId":77,"briefTitle":78,"status":112,"phases":519,"primaryCompletion":79,"completion":79,"start":345,"enrollment":346,"conditions":520,"interventions":521},[90],[348,349],[80,351,352,353,354,355,356,357,358,359],{"trials":523,"activeCount":100},[],{"trials":525,"activeCount":100},[],{"intervention":45,"totalTrials":96,"cells":527},{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":540,"NA":542},{"trials":529,"activeCount":100},[],{"trials":531,"activeCount":100},[],{"trials":533,"activeCount":100},[],{"trials":535,"activeCount":96,"soonestReadout":44},[536],{"nctId":42,"briefTitle":43,"status":181,"phases":537,"primaryCompletion":44,"completion":243,"start":244,"enrollment":245,"conditions":538,"interventions":539},[90],[247],[45,231],{"trials":541,"activeCount":100},[],{"trials":543,"activeCount":100},[],{"intervention":50,"totalTrials":545,"cells":546},3,{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":563,"PHASE4":578,"NA":594},{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":96,"soonestReadout":49},[553],{"nctId":47,"briefTitle":48,"status":112,"phases":554,"primaryCompletion":49,"completion":555,"start":556,"enrollment":557,"conditions":558,"interventions":562},[89],"2026-06","2015-12",303,[559,560,561],"Polycystic Ovary Syndrome","Insulin Resistance","Hyperandrogenism",[50],{"trials":564,"activeCount":100},[565],{"nctId":566,"briefTitle":567,"status":568,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":577},"NCT05182970","Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)","UNKNOWN",[90],"2026-05","2021-12-02",5160,[574,120,575,576],"PreDiabetes","Non ST Elevation Myocardial Infarction","ST Elevation Myocardial Infarction",[50],{"trials":579,"activeCount":100},[580],{"nctId":581,"briefTitle":582,"status":252,"phases":583,"primaryCompletion":584,"completion":585,"start":556,"enrollment":586,"conditions":587,"interventions":591},"NCT02621489","Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects",[91],"2022-08","2022-10",38,[588,589,590],"Atherosclerosis","Diabetes","Restenosis",[592,593,50],"Bydureon","Humulin kwickpen",{"trials":595,"activeCount":100},[],{"intervention":597,"totalTrials":194,"cells":598},"Botulinum Toxin Type A",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":614,"PHASE4":627,"NA":629},{"trials":600,"activeCount":100},[],{"trials":602,"activeCount":100},[],{"trials":604,"activeCount":96,"soonestReadout":54},[605],{"nctId":52,"briefTitle":53,"status":112,"phases":606,"primaryCompletion":54,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":612},[89],"2027-08-31","2023-09-20",50,[611],"Temporomandibular Disorders",[55,613],"Isotonic saline 0,9%",{"trials":615,"activeCount":100},[616],{"nctId":617,"briefTitle":618,"status":252,"phases":619,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT02773641","Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia",[90],"2019-06","2016-05",90,[624],"Vulvodynia",[597,626],"Sterile Saline Solution",{"trials":628,"activeCount":100},[],{"trials":630,"activeCount":100},[],{"intervention":632,"totalTrials":96,"cells":633},"BOOST cells",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":638,"PHASE3":650,"PHASE4":652,"NA":654},{"trials":635,"activeCount":100},[],{"trials":637,"activeCount":100},[],{"trials":639,"activeCount":96,"soonestReadout":644},[640],{"nctId":641,"briefTitle":642,"status":181,"phases":643,"primaryCompletion":644,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":649},"NCT03706482","Boost Brittle Bones Before Birth",[88,89],"2030-04","2019-08-12",18,[648],"Osteogenesis Imperfecta",[632],{"trials":651,"activeCount":100},[],{"trials":653,"activeCount":100},[],{"trials":655,"activeCount":100},[],{"intervention":657,"totalTrials":96,"cells":658},"Eplerenone",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":660,"activeCount":100},[],{"trials":662,"activeCount":100},[],{"trials":664,"activeCount":96,"soonestReadout":669},[665],{"nctId":666,"briefTitle":667,"status":112,"phases":668,"primaryCompletion":669,"completion":670,"start":671,"enrollment":672,"conditions":673,"interventions":676},"NCT07029503","Swedish Cardiac And Renal Failure Study-1",[89],"2027-02","2027-10","2026-02",40,[674,675],"HFrEF - Heart Failure With Reduced Ejection Fraction","Chronic Kidney Disease",[657],{"trials":678,"activeCount":100},[],{"trials":680,"activeCount":100},[],{"trials":682,"activeCount":100},[],{"intervention":613,"totalTrials":96,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":686,"activeCount":100},[],{"trials":688,"activeCount":100},[],{"trials":690,"activeCount":96,"soonestReadout":54},[691],{"nctId":52,"briefTitle":53,"status":112,"phases":692,"primaryCompletion":54,"completion":607,"start":608,"enrollment":609,"conditions":693,"interventions":694},[89],[611],[55,613],{"trials":696,"activeCount":100},[],{"trials":698,"activeCount":100},[],{"trials":700,"activeCount":100},[],{"intervention":702,"totalTrials":96,"cells":703},"CellProtect",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":705,"activeCount":100},[],{"trials":707,"activeCount":100},[],{"trials":709,"activeCount":96,"soonestReadout":183},[710],{"nctId":711,"briefTitle":712,"status":112,"phases":713,"primaryCompletion":183,"completion":714,"start":715,"enrollment":716,"conditions":717,"interventions":719},"NCT04558931","Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma",[89],"2032-12-31","2021-06-02",62,[718],"Multiple Myeloma",[702,720],"Isatuximab",{"trials":722,"activeCount":100},[],{"trials":724,"activeCount":100},[],{"trials":726,"activeCount":100},[],{"intervention":720,"totalTrials":96,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":730,"activeCount":100},[],{"trials":732,"activeCount":100},[],{"trials":734,"activeCount":96,"soonestReadout":183},[735],{"nctId":711,"briefTitle":712,"status":112,"phases":736,"primaryCompletion":183,"completion":714,"start":715,"enrollment":716,"conditions":737,"interventions":738},[89],[718],[702,720],{"trials":740,"activeCount":100},[],{"trials":742,"activeCount":100},[],{"trials":744,"activeCount":100},[],{"intervention":746,"totalTrials":96,"cells":747},"Obesity medication with liraglutide or semaglutide",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":749,"activeCount":100},[],{"trials":751,"activeCount":100},[],{"trials":753,"activeCount":100},[],{"trials":755,"activeCount":100},[],{"trials":757,"activeCount":100},[],{"trials":759,"activeCount":96,"soonestReadout":764},[760],{"nctId":761,"briefTitle":762,"status":112,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":672,"conditions":767,"interventions":770},"NCT06836284","The Evira Study: Additional Support During Obesity Treatment",[92],"2027-04-01","2027-05-01","2026-02-13",[768,769],"Childhood Obesity","Treatment Adherence",[746],{"intervention":65,"totalTrials":96,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":779,"PHASE4":781,"NA":783},{"trials":774,"activeCount":100},[],{"trials":776,"activeCount":100},[],{"trials":778,"activeCount":100},[],{"trials":780,"activeCount":100},[],{"trials":782,"activeCount":100},[],{"trials":784,"activeCount":96,"soonestReadout":64},[785],{"nctId":62,"briefTitle":63,"status":112,"phases":786,"primaryCompletion":64,"completion":787,"start":788,"enrollment":257,"conditions":789,"interventions":791},[92],"2027-01-30","2018-06-30",[790],"Essential Tremor",[65],{"intervention":793,"totalTrials":96,"cells":794},"Immunomodulation",{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"trials":800,"activeCount":100},[],{"trials":802,"activeCount":100},[],{"trials":804,"activeCount":100},[],{"trials":806,"activeCount":96,"soonestReadout":811},[807],{"nctId":808,"briefTitle":809,"status":112,"phases":810,"primaryCompletion":811,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":821},"NCT06248957","SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION",[],"2030-12-31","2031-12-31","2024-01-01",500,[816,817,818,819,820],"Immunodeficiency","Autoimmune Diseases","Autoinflammatory Syndrome","Allergy","Dysregulated Host Response",[793],{"intervention":823,"totalTrials":96,"cells":824},"Medical Therapy",{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":826,"activeCount":100},[],{"trials":828,"activeCount":100},[],{"trials":830,"activeCount":100},[],{"trials":832,"activeCount":100},[],{"trials":834,"activeCount":100},[],{"trials":836,"activeCount":96,"soonestReadout":841},[837],{"nctId":838,"briefTitle":839,"status":181,"phases":840,"primaryCompletion":841,"completion":842,"start":843,"enrollment":346,"conditions":844,"interventions":846},"NCT02830152","Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage",[92],"2027-12","2028-12","2017-05-03",[28,21,845],"Intracerebral Hemorrhage",[823],{"intervention":75,"totalTrials":96,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":850,"activeCount":100},[],{"trials":852,"activeCount":100},[],{"trials":854,"activeCount":100},[],{"trials":856,"activeCount":100},[],{"trials":858,"activeCount":100},[],{"trials":860,"activeCount":96,"soonestReadout":74},[861],{"nctId":72,"briefTitle":73,"status":112,"phases":862,"primaryCompletion":74,"completion":714,"start":863,"enrollment":864,"conditions":865,"interventions":867},[92],"2023-02-08",60,[866],"Type 2 Diabetes",[75,868,869],"Empagliflozin 25 MG","Semaglutide 7 MG",{"intervention":868,"totalTrials":96,"cells":871},{"EARLY_PHASE1":872,"PHASE1":874,"PHASE2":876,"PHASE3":878,"PHASE4":880,"NA":882},{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[],{"trials":877,"activeCount":100},[],{"trials":879,"activeCount":100},[],{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":96,"soonestReadout":74},[884],{"nctId":72,"briefTitle":73,"status":112,"phases":885,"primaryCompletion":74,"completion":714,"start":863,"enrollment":864,"conditions":886,"interventions":887},[92],[866],[75,868,869],{"intervention":869,"totalTrials":96,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":896,"PHASE4":898,"NA":900},{"trials":891,"activeCount":100},[],{"trials":893,"activeCount":100},[],{"trials":895,"activeCount":100},[],{"trials":897,"activeCount":100},[],{"trials":899,"activeCount":100},[],{"trials":901,"activeCount":96,"soonestReadout":74},[902],{"nctId":72,"briefTitle":73,"status":112,"phases":903,"primaryCompletion":74,"completion":714,"start":863,"enrollment":864,"conditions":904,"interventions":905},[92],[866],[75,868,869],{"intervention":70,"totalTrials":96,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":912,"PHASE3":914,"PHASE4":916,"NA":918},{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":100},[],{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":96,"soonestReadout":69},[920],{"nctId":67,"briefTitle":68,"status":207,"phases":921,"primaryCompletion":69,"completion":922,"start":923,"enrollment":609,"conditions":924,"interventions":928},[92],"2026-12-20","2026-06-04",[925,926,927],"Myogenic Temporomandibular Joint Disorders","Myofacial Pain","Masseter Muscle",[70],{"intervention":40,"totalTrials":96,"cells":930},{"EARLY_PHASE1":931,"PHASE1":933,"PHASE2":935,"PHASE3":937,"PHASE4":939,"NA":941},{"trials":932,"activeCount":100},[],{"trials":934,"activeCount":100},[],{"trials":936,"activeCount":100},[],{"trials":938,"activeCount":100},[],{"trials":940,"activeCount":100},[],{"trials":942,"activeCount":96,"soonestReadout":39},[943],{"nctId":37,"briefTitle":38,"status":181,"phases":944,"primaryCompletion":39,"completion":79,"start":945,"enrollment":946,"conditions":947,"interventions":950},[92],"2002-03",233,[948,949],"Asthma","COPD",[40],{"intervention":952,"totalTrials":194,"cells":953},"Misoprostol",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":973,"NA":985},{"trials":955,"activeCount":100},[],{"trials":957,"activeCount":100},[],{"trials":959,"activeCount":100},[],{"trials":961,"activeCount":100},[962],{"nctId":963,"briefTitle":964,"status":252,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":972},"NCT05424445","MISOBEST - Orally Misoprostol Solution (Cytotec®) Versus Orally Misoprostol as a Tablet (Angusta®) for Induction of Labor",[90],"2022-12-31","2023-05-21","2022-01-21",884,[971],"Induced Vaginal Delivery",[952],{"trials":974,"activeCount":100},[975],{"nctId":976,"briefTitle":977,"status":568,"phases":978,"primaryCompletion":979,"completion":979,"start":980,"enrollment":981,"conditions":982,"interventions":984},"NCT02918110","Vaginal Misodel® in Comparison With Orally Administrated Misoprostol (Cytotec®) at Induction of Labour",[91],"2017-09","2016-09",320,[983],"Induced Deliveries",[952],{"trials":986,"activeCount":100},[],{"intervention":988,"totalTrials":194,"cells":989},"Mifepristone",{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":1007,"PHASE4":1009,"NA":1024},{"trials":991,"activeCount":100},[],{"trials":993,"activeCount":100},[],{"trials":995,"activeCount":100},[996],{"nctId":997,"briefTitle":998,"status":252,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1006},"NCT01898312","BRCA1\u002F2 and Effect of Mifepristone on the Breast",[89],"2021-12-31","2022-01","2013-09",45,[1005],"Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2",[988],{"trials":1008,"activeCount":100},[],{"trials":1010,"activeCount":100},[1011],{"nctId":1012,"briefTitle":1013,"status":252,"phases":1014,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1022},"NCT01920022","Quickstart of Nexplanon® at Medical Abortion",[91],"2015-10","2013-10",551,[1019,1020,1021],"Early Pregnancy Termination","Medical Abortion","Postabortion Contraception",[988,1023],"etonorgestrel",{"trials":1025,"activeCount":100},[],{"intervention":1027,"totalTrials":194,"cells":1028},"Atorvastatin",{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1046,"PHASE3":1048,"PHASE4":1050,"NA":1063},{"trials":1030,"activeCount":100},[],{"trials":1032,"activeCount":100},[1033],{"nctId":1034,"briefTitle":1035,"status":252,"phases":1036,"primaryCompletion":556,"completion":556,"start":1037,"enrollment":11,"conditions":1038,"interventions":1043},"NCT02286544","Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers",[88],"2014-10",[1039,1040,1041,1042],"Myocardial Infarction","Inflammation","Acute Coronary Syndrome (ACS)","Reperfusion Injury",[1044,1045,1027],"Salmonella typhi vaccine","Oxygen",{"trials":1047,"activeCount":100},[],{"trials":1049,"activeCount":100},[],{"trials":1051,"activeCount":100},[1052],{"nctId":1053,"briefTitle":1054,"status":252,"phases":1055,"primaryCompletion":1056,"completion":1057,"start":1058,"enrollment":19,"conditions":1059,"interventions":1062},"NCT01497912","Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes",[91],"2009-01","2010-01","2005-01",[1060,1061],"Type 1 Diabetes Mellitus","Dyslipidemia",[1027],{"trials":1064,"activeCount":100},[],{"intervention":1066,"totalTrials":194,"cells":1067},"Cimzia",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1074,"PHASE4":1076,"NA":1102},{"trials":1069,"activeCount":100},[],{"trials":1071,"activeCount":100},[],{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[1078,1092],{"nctId":1079,"briefTitle":1080,"status":568,"phases":1081,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1086,"interventions":1088},"NCT01491815","Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction",[91],"2023-07","2023-12","2012-12-14",812,[1087],"Rheumatoid Arthritis",[1089,1066,1090,1091],"Non-biological DMARD's","Orencia","RoActemra",{"nctId":1093,"briefTitle":1094,"status":568,"phases":1095,"primaryCompletion":1096,"completion":1083,"start":1097,"enrollment":1098,"conditions":1099,"interventions":1100},"NCT02466581","Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity",[91],"2023-07-22","2015-02-03",25,[1087],[1101,1066,1090,1091],"Sulphasalazine + Hydroxychloroquine OR Prednisolone",{"trials":1103,"activeCount":100},[],{"intervention":1090,"totalTrials":194,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1114,"NA":1124},{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"trials":1113,"activeCount":100},[],{"trials":1115,"activeCount":100},[1116,1120],{"nctId":1079,"briefTitle":1080,"status":568,"phases":1117,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1118,"interventions":1119},[91],[1087],[1089,1066,1090,1091],{"nctId":1093,"briefTitle":1094,"status":568,"phases":1121,"primaryCompletion":1096,"completion":1083,"start":1097,"enrollment":1098,"conditions":1122,"interventions":1123},[91],[1087],[1101,1066,1090,1091],{"trials":1125,"activeCount":100},[],{"intervention":1091,"totalTrials":194,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1134,"PHASE4":1136,"NA":1146},{"trials":1129,"activeCount":100},[],{"trials":1131,"activeCount":100},[],{"trials":1133,"activeCount":100},[],{"trials":1135,"activeCount":100},[],{"trials":1137,"activeCount":100},[1138,1142],{"nctId":1079,"briefTitle":1080,"status":568,"phases":1139,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1140,"interventions":1141},[91],[1087],[1089,1066,1090,1091],{"nctId":1093,"briefTitle":1094,"status":568,"phases":1143,"primaryCompletion":1096,"completion":1083,"start":1097,"enrollment":1098,"conditions":1144,"interventions":1145},[91],[1087],[1101,1066,1090,1091],{"trials":1147,"activeCount":100},[],{"intervention":1149,"totalTrials":194,"cells":1150},"Aspirin",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1159,"NA":1181},{"trials":1152,"activeCount":100},[],{"trials":1154,"activeCount":100},[],{"trials":1156,"activeCount":100},[],{"trials":1158,"activeCount":100},[],{"trials":1160,"activeCount":100},[1161,1171],{"nctId":1162,"briefTitle":1163,"status":252,"phases":1164,"primaryCompletion":1165,"completion":1165,"start":1166,"enrollment":1098,"conditions":1167,"interventions":1169},"NCT00812032","Evaluation of Antiplatelet Effects of Different Dosages of Aspirin in Type 2 Diabetic Patients",[91],"2010-10","2008-01",[1168],"Type 2 Diabetes Mellitus",[1149,1170],"aspirin",{"nctId":1172,"briefTitle":1173,"status":252,"phases":1174,"primaryCompletion":1175,"completion":1176,"start":1177,"enrollment":9,"conditions":1178,"interventions":1180},"NCT01397513","Effects of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes",[91],"2010-07","2011-02","2006-03",[1179],"Diabetes Mellitus, Type 1",[1149],{"trials":1182,"activeCount":100},[],{"intervention":227,"totalTrials":194,"cells":1184},{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1209},{"trials":1186,"activeCount":100},[],{"trials":1188,"activeCount":100},[],{"trials":1190,"activeCount":100},[],{"trials":1192,"activeCount":100},[],{"trials":1194,"activeCount":100},[1195,1199],{"nctId":216,"briefTitle":217,"status":218,"phases":1196,"primaryCompletion":220,"completion":221,"start":222,"enrollment":100,"conditions":1197,"interventions":1198},[91],[224,225],[227,193],{"nctId":1200,"briefTitle":1201,"status":252,"phases":1202,"primaryCompletion":1203,"completion":1204,"start":1205,"enrollment":257,"conditions":1206,"interventions":1207},"NCT00733421","The Effect of Anti-inflammatory Analgesics on Pain Following Hallux Valgus Surgery",[91],"2009-06","2009-08","2008-10",[225],[227,1208],"tramadol",{"trials":1210,"activeCount":100},[],{"intervention":1212,"totalTrials":96,"cells":1213},"NPH insulin",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1218,"PHASE3":1220,"PHASE4":1222,"NA":1236},{"trials":1215,"activeCount":100},[],{"trials":1217,"activeCount":100},[],{"trials":1219,"activeCount":100},[],{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":100},[1224],{"nctId":1225,"briefTitle":1226,"status":568,"phases":1227,"primaryCompletion":1228,"start":1229,"enrollment":1230,"conditions":1231,"interventions":1233},"NCT01271517","Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis",[91],"2011-03","2005-09",120,[1232],"Diabetes Mellitus Type 1",[1212,1234,1235],"Glargine","Detemir",{"trials":1237,"activeCount":100},[],{"intervention":1234,"totalTrials":96,"cells":1239},{"EARLY_PHASE1":1240,"PHASE1":1242,"PHASE2":1244,"PHASE3":1246,"PHASE4":1248,"NA":1254},{"trials":1241,"activeCount":100},[],{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":100},[1250],{"nctId":1225,"briefTitle":1226,"status":568,"phases":1251,"primaryCompletion":1228,"start":1229,"enrollment":1230,"conditions":1252,"interventions":1253},[91],[1232],[1212,1234,1235],{"trials":1255,"activeCount":100},[],{"intervention":1235,"totalTrials":96,"cells":1257},{"EARLY_PHASE1":1258,"PHASE1":1260,"PHASE2":1262,"PHASE3":1264,"PHASE4":1266,"NA":1272},{"trials":1259,"activeCount":100},[],{"trials":1261,"activeCount":100},[],{"trials":1263,"activeCount":100},[],{"trials":1265,"activeCount":100},[],{"trials":1267,"activeCount":100},[1268],{"nctId":1225,"briefTitle":1226,"status":568,"phases":1269,"primaryCompletion":1228,"start":1229,"enrollment":1230,"conditions":1270,"interventions":1271},[91],[1232],[1212,1234,1235],{"trials":1273,"activeCount":100},[],{"intervention":1275,"totalTrials":96,"cells":1276},"paroxetine",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1298},{"trials":1278,"activeCount":100},[],{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[],{"trials":1286,"activeCount":100},[1287],{"nctId":1288,"briefTitle":1289,"status":252,"phases":1290,"completion":1291,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1297},"NCT00516113","A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria",[91],"2002-11","2000-10",24,[1295,1296],"Premenstrual Dysphoric Disorder","Premenstrual Syndrome",[1275],{"trials":1299,"activeCount":100},[],{"intervention":1301,"totalTrials":96,"cells":1302},"Vitamin D3",{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1309,"PHASE4":1311,"NA":1325},{"trials":1304,"activeCount":100},[],{"trials":1306,"activeCount":100},[],{"trials":1308,"activeCount":100},[],{"trials":1310,"activeCount":100},[],{"trials":1312,"activeCount":100},[1313],{"nctId":1314,"briefTitle":1315,"status":252,"phases":1316,"primaryCompletion":1317,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1324},"NCT01497132","Effects of Vitamin D on Beta Cell Function and Insulin Sensitivity in Pre-diabetes and Diabetes Mellitus Type 2",[91],"2013-05","2012-01",44,[1321,1322,1323],"Diabetes Mellitus, Type 2","Glucose Intolerance","Vitamin D Deficiency",[1301],{"trials":1326,"activeCount":100},[],{"intervention":1328,"totalTrials":96,"cells":1329},"Ramipril",{"EARLY_PHASE1":1330,"PHASE1":1332,"PHASE2":1334,"PHASE3":1336,"PHASE4":1338,"NA":1351},{"trials":1331,"activeCount":100},[],{"trials":1333,"activeCount":100},[],{"trials":1335,"activeCount":100},[],{"trials":1337,"activeCount":100},[],{"trials":1339,"activeCount":100},[1340],{"nctId":1341,"briefTitle":1342,"status":252,"phases":1343,"primaryCompletion":1344,"completion":1345,"start":1228,"enrollment":1346,"conditions":1347,"interventions":1349},"NCT02901977","Doxazosin and Ramipril in Hypertension",[91],"2015-02","2015-04",71,[1348],"Hypertension",[1328,1350],"Doxazosin",{"trials":1352,"activeCount":100},[],{"intervention":1350,"totalTrials":96,"cells":1354},{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1369},{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":100},[],{"trials":1362,"activeCount":100},[],{"trials":1364,"activeCount":100},[1365],{"nctId":1341,"briefTitle":1342,"status":252,"phases":1366,"primaryCompletion":1344,"completion":1345,"start":1228,"enrollment":1346,"conditions":1367,"interventions":1368},[91],[1348],[1328,1350],{"trials":1370,"activeCount":100},[],{"intervention":1023,"totalTrials":96,"cells":1372},{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1381,"NA":1387},{"trials":1374,"activeCount":100},[],{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":100},[],{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[1383],{"nctId":1012,"briefTitle":1013,"status":252,"phases":1384,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":1017,"conditions":1385,"interventions":1386},[91],[1019,1020,1021],[988,1023],{"trials":1388,"activeCount":100},[],{"intervention":1390,"totalTrials":96,"cells":1391},"Zoledronic Acid",{"EARLY_PHASE1":1392,"PHASE1":1394,"PHASE2":1396,"PHASE3":1398,"PHASE4":1400,"NA":1413},{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"trials":1397,"activeCount":100},[],{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":100},[1402],{"nctId":1403,"briefTitle":1404,"status":568,"phases":1405,"primaryCompletion":1406,"completion":1407,"start":1408,"enrollment":1409,"conditions":1410,"interventions":1412},"NCT04115397","Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints",[91],"2021-12","2022-12","2020-01",80,[1411],"Seropositive Muskuloskeletal Complaints",[1390],{"trials":1414,"activeCount":100},[],{"intervention":1416,"totalTrials":96,"cells":1417},"I.V. SOLUTIONS",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1424,"PHASE4":1426,"NA":1439},{"trials":1419,"activeCount":100},[],{"trials":1421,"activeCount":100},[],{"trials":1423,"activeCount":100},[],{"trials":1425,"activeCount":100},[],{"trials":1427,"activeCount":100},[1428],{"nctId":1429,"briefTitle":1430,"status":252,"phases":1431,"primaryCompletion":1432,"completion":1433,"start":1434,"enrollment":1435,"conditions":1436,"interventions":1438},"NCT04282252","The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation",[91],"2021-10-22","2022-04-22","2020-02-02",54,[1437],"Septic Shock",[1416],{"trials":1440,"activeCount":100},[],{"intervention":1442,"totalTrials":96,"cells":1443},"pregabalin",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1448,"PHASE3":1450,"PHASE4":1452,"NA":1467},{"trials":1445,"activeCount":100},[],{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"trials":1453,"activeCount":100},[1454],{"nctId":1455,"briefTitle":1456,"status":1457,"phases":1458,"primaryCompletion":1317,"completion":1459,"start":1460,"enrollment":646,"conditions":1461,"interventions":1466},"NCT00403780","Randomized Study of Pregabalin for Pain Reduction in Patients With Rest Pain and Lower Limb Ischemia","TERMINATED",[91],"2015-07","2006-06",[1462,1463,1464,1465],"Critical Limb Ischemia","Arterial Occlusive Disease","Pain","Ischemia",[1442],{"trials":1468,"activeCount":100},[],{"intervention":1470,"totalTrials":96,"cells":1471},"Sitagliptin",{"EARLY_PHASE1":1472,"PHASE1":1474,"PHASE2":1476,"PHASE3":1478,"PHASE4":1480,"NA":1494},{"trials":1473,"activeCount":100},[],{"trials":1475,"activeCount":100},[],{"trials":1477,"activeCount":100},[],{"trials":1479,"activeCount":100},[],{"trials":1481,"activeCount":100},[1482],{"nctId":1483,"briefTitle":1484,"status":252,"phases":1485,"primaryCompletion":1486,"completion":1486,"start":1487,"enrollment":1488,"conditions":1489,"interventions":1493},"NCT00627744","Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction",[91],"2010-11","2008-05",85,[1039,1490,1491,1492],"Unstable Angina Pectoris","Diabetes Mellitus","Impaired Glucose Tolerance",[1470],{"trials":1495,"activeCount":100},[],{"intervention":1497,"totalTrials":96,"cells":1498},"Acarbose",{"EARLY_PHASE1":1499,"PHASE1":1501,"PHASE2":1503,"PHASE3":1505,"PHASE4":1507,"NA":1518},{"trials":1500,"activeCount":100},[],{"trials":1502,"activeCount":100},[],{"trials":1504,"activeCount":100},[],{"trials":1506,"activeCount":100},[],{"trials":1508,"activeCount":100},[1509],{"nctId":1510,"briefTitle":1511,"status":252,"phases":1512,"primaryCompletion":1513,"start":1514,"enrollment":716,"conditions":1515,"interventions":1517},"NCT01244971","Exercise and Acarbose in Type 2 Diabetes",[91],"2004-06","2004-01",[1516],"Diabetes Mellitus Type 2",[1497],{"trials":1519,"activeCount":100},[],{"intervention":1089,"totalTrials":96,"cells":1521},{"EARLY_PHASE1":1522,"PHASE1":1524,"PHASE2":1526,"PHASE3":1528,"PHASE4":1530,"NA":1536},{"trials":1523,"activeCount":100},[],{"trials":1525,"activeCount":100},[],{"trials":1527,"activeCount":100},[],{"trials":1529,"activeCount":100},[],{"trials":1531,"activeCount":100},[1532],{"nctId":1079,"briefTitle":1080,"status":568,"phases":1533,"primaryCompletion":1082,"completion":1083,"start":1084,"enrollment":1085,"conditions":1534,"interventions":1535},[91],[1087],[1089,1066,1090,1091],{"trials":1537,"activeCount":100},[],{"intervention":1539,"totalTrials":96,"cells":1540},"conventional DMARD combination",{"EARLY_PHASE1":1541,"PHASE1":1543,"PHASE2":1545,"PHASE3":1547,"PHASE4":1549,"NA":1562},{"trials":1542,"activeCount":100},[],{"trials":1544,"activeCount":100},[],{"trials":1546,"activeCount":100},[],{"trials":1548,"activeCount":100},[],{"trials":1550,"activeCount":100},[1551],{"nctId":1552,"briefTitle":1553,"status":252,"phases":1554,"primaryCompletion":1555,"completion":1556,"start":1557,"enrollment":1558,"conditions":1559,"interventions":1560},"NCT00764725","Comparison of MTX+Anti-TNF to MTX+Conventional DMARDs in Patients With Early Rheumatoid Arthritis (RA) Who Failed MTX Alone (SWEFOT)",[91],"2007-04","2008-12","2002-12",487,[1087],[1539,1561],"MTX plus anti-TNF",{"trials":1563,"activeCount":100},[],{"intervention":1561,"totalTrials":96,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1572,"PHASE4":1574,"NA":1580},{"trials":1567,"activeCount":100},[],{"trials":1569,"activeCount":100},[],{"trials":1571,"activeCount":100},[],{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[1576],{"nctId":1552,"briefTitle":1553,"status":252,"phases":1577,"primaryCompletion":1555,"completion":1556,"start":1557,"enrollment":1558,"conditions":1578,"interventions":1579},[91],[1087],[1539,1561],{"trials":1581,"activeCount":100},[],{"intervention":592,"totalTrials":96,"cells":1583},{"EARLY_PHASE1":1584,"PHASE1":1586,"PHASE2":1588,"PHASE3":1590,"PHASE4":1592,"NA":1598},{"trials":1585,"activeCount":100},[],{"trials":1587,"activeCount":100},[],{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[1594],{"nctId":581,"briefTitle":582,"status":252,"phases":1595,"primaryCompletion":584,"completion":585,"start":556,"enrollment":586,"conditions":1596,"interventions":1597},[91],[588,589,590],[592,593,50],{"trials":1599,"activeCount":100},[],{"intervention":593,"totalTrials":96,"cells":1601},{"EARLY_PHASE1":1602,"PHASE1":1604,"PHASE2":1606,"PHASE3":1608,"PHASE4":1610,"NA":1616},{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[],{"trials":1611,"activeCount":100},[1612],{"nctId":581,"briefTitle":582,"status":252,"phases":1613,"primaryCompletion":584,"completion":585,"start":556,"enrollment":586,"conditions":1614,"interventions":1615},[91],[588,589,590],[592,593,50],{"trials":1617,"activeCount":100},[],{"intervention":1619,"totalTrials":96,"cells":1620},"MethylPREDNISolone 40 Mg\u002FmL Injectable Suspension",{"EARLY_PHASE1":1621,"PHASE1":1623,"PHASE2":1625,"PHASE3":1627,"PHASE4":1629,"NA":1645},{"trials":1622,"activeCount":100},[],{"trials":1624,"activeCount":100},[],{"trials":1626,"activeCount":100},[],{"trials":1628,"activeCount":100},[],{"trials":1630,"activeCount":100},[1631],{"nctId":1632,"briefTitle":1633,"status":252,"phases":1634,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1319,"conditions":1638,"interventions":1643},"NCT04622917","Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis.",[91],"2022-06-20","2023-05-31","2019-04-10",[1639,1640,1641,1642],"Rhinitis, Allergic, Seasonal","Hay Fever","Pollen Allergy","Allergic Rhinitis",[1619,1644],"NaCl 9 MG\u002FML Injectable Solution",{"trials":1646,"activeCount":100},[],{"intervention":1644,"totalTrials":96,"cells":1648},{"EARLY_PHASE1":1649,"PHASE1":1651,"PHASE2":1653,"PHASE3":1655,"PHASE4":1657,"NA":1663},{"trials":1650,"activeCount":100},[],{"trials":1652,"activeCount":100},[],{"trials":1654,"activeCount":100},[],{"trials":1656,"activeCount":100},[],{"trials":1658,"activeCount":100},[1659],{"nctId":1632,"briefTitle":1633,"status":252,"phases":1660,"primaryCompletion":1635,"completion":1636,"start":1637,"enrollment":1319,"conditions":1661,"interventions":1662},[91],[1639,1640,1641,1642],[1619,1644],{"trials":1664,"activeCount":100},[],{"intervention":1666,"totalTrials":96,"cells":1667},"Metoprolol Succinate",{"EARLY_PHASE1":1668,"PHASE1":1670,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1690},{"trials":1669,"activeCount":100},[],{"trials":1671,"activeCount":100},[],{"trials":1673,"activeCount":100},[],{"trials":1675,"activeCount":100},[],{"trials":1677,"activeCount":100},[1678],{"nctId":1679,"briefTitle":1680,"status":568,"phases":1681,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":1686,"interventions":1688},"NCT03278509","Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)",[91],"2023-11-16","2025-12-31","2017-09-11",5000,[120,1687,576],"Non-ST Elevation Myocardial Infarction",[1666,1689],"Bisoprolol",{"trials":1691,"activeCount":100},[],{"intervention":1689,"totalTrials":96,"cells":1693},{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1708},{"trials":1695,"activeCount":100},[],{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":100},[1704],{"nctId":1679,"briefTitle":1680,"status":568,"phases":1705,"primaryCompletion":1682,"completion":1683,"start":1684,"enrollment":1685,"conditions":1706,"interventions":1707},[91],[120,1687,576],[1666,1689],{"trials":1709,"activeCount":100},[],{"intervention":1711,"totalTrials":96,"cells":1712},"Insulin aspart",{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1721,"NA":1732},{"trials":1714,"activeCount":100},[],{"trials":1716,"activeCount":100},[],{"trials":1718,"activeCount":100},[],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[1723],{"nctId":1724,"briefTitle":1725,"status":252,"phases":1726,"primaryCompletion":1727,"completion":1727,"start":1728,"enrollment":646,"conditions":1729,"interventions":1731},"NCT00771693","Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With Non-insulin-dependent Diabetes Mellitus (NIDDM)",[91],"2011-07","2007-05",[1168,1730],"Postprandial Hyperglycemia",[1711],{"trials":1733,"activeCount":100},[],{"intervention":1735,"totalTrials":96,"cells":1736},"Granisetron",{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1741,"PHASE3":1743,"PHASE4":1745,"NA":1757},{"trials":1738,"activeCount":100},[],{"trials":1740,"activeCount":100},[],{"trials":1742,"activeCount":100},[],{"trials":1744,"activeCount":100},[],{"trials":1746,"activeCount":100},[1747],{"nctId":1748,"briefTitle":1749,"status":252,"phases":1750,"primaryCompletion":1037,"completion":1751,"start":1752,"enrollment":672,"conditions":1753,"interventions":1755},"NCT02230371","Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles",[91],"2014-12","2007-03",[1754,611],"Myofascial Pain",[1735,1756],"Control",{"trials":1758,"activeCount":100},[],{"intervention":1756,"totalTrials":96,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1769,"NA":1775},{"trials":1762,"activeCount":100},[],{"trials":1764,"activeCount":100},[],{"trials":1766,"activeCount":100},[],{"trials":1768,"activeCount":100},[],{"trials":1770,"activeCount":100},[1771],{"nctId":1748,"briefTitle":1749,"status":252,"phases":1772,"primaryCompletion":1037,"completion":1751,"start":1752,"enrollment":672,"conditions":1773,"interventions":1774},[91],[1754,611],[1735,1756],{"trials":1776,"activeCount":100},[],{"intervention":1778,"totalTrials":96,"cells":1779},"Angemin vs Activelle",{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1800},{"trials":1781,"activeCount":100},[],{"trials":1783,"activeCount":100},[],{"trials":1785,"activeCount":100},[],{"trials":1787,"activeCount":100},[],{"trials":1789,"activeCount":100},[1790],{"nctId":1791,"briefTitle":1792,"status":568,"phases":1793,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1230,"conditions":1797,"interventions":1799},"NCT00785317","Effects of Estradiol on Menopausal Breast",[91],"2009-10","2010-04","2008-11",[1798],"Hormone Replacement Therapy",[1778],{"trials":1801,"activeCount":100},[],{"intervention":1208,"totalTrials":96,"cells":1803},{"EARLY_PHASE1":1804,"PHASE1":1806,"PHASE2":1808,"PHASE3":1810,"PHASE4":1812,"NA":1818},{"trials":1805,"activeCount":100},[],{"trials":1807,"activeCount":100},[],{"trials":1809,"activeCount":100},[],{"trials":1811,"activeCount":100},[],{"trials":1813,"activeCount":100},[1814],{"nctId":1200,"briefTitle":1201,"status":252,"phases":1815,"primaryCompletion":1203,"completion":1204,"start":1205,"enrollment":257,"conditions":1816,"interventions":1817},[91],[225],[227,1208],{"trials":1819,"activeCount":100},[],{"intervention":1821,"totalTrials":96,"cells":1822},"Ezetimibe",{"EARLY_PHASE1":1823,"PHASE1":1825,"PHASE2":1827,"PHASE3":1829,"PHASE4":1831,"NA":1843},{"trials":1824,"activeCount":100},[],{"trials":1826,"activeCount":100},[],{"trials":1828,"activeCount":100},[],{"trials":1830,"activeCount":100},[],{"trials":1832,"activeCount":100},[1833],{"nctId":1834,"briefTitle":1835,"status":252,"phases":1836,"primaryCompletion":1837,"completion":1837,"start":1838,"enrollment":1839,"conditions":1840,"interventions":1842},"NCT01035320","Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment",[91],"2012-06","2006-01",39,[1491,1841],"Impaired Renal Function",[1821],{"trials":1844,"activeCount":100},[],{"intervention":1101,"totalTrials":96,"cells":1846},{"EARLY_PHASE1":1847,"PHASE1":1849,"PHASE2":1851,"PHASE3":1853,"PHASE4":1855,"NA":1861},{"trials":1848,"activeCount":100},[],{"trials":1850,"activeCount":100},[],{"trials":1852,"activeCount":100},[],{"trials":1854,"activeCount":100},[],{"trials":1856,"activeCount":100},[1857],{"nctId":1093,"briefTitle":1094,"status":568,"phases":1858,"primaryCompletion":1096,"completion":1083,"start":1097,"enrollment":1098,"conditions":1859,"interventions":1860},[91],[1087],[1101,1066,1090,1091],{"trials":1862,"activeCount":100},[],{"intervention":1864,"totalTrials":545,"cells":1865},"ALK Diluent",{"EARLY_PHASE1":1866,"PHASE1":1868,"PHASE2":1870,"PHASE3":1872,"PHASE4":1903,"NA":1905},{"trials":1867,"activeCount":100},[],{"trials":1869,"activeCount":100},[],{"trials":1871,"activeCount":100},[],{"trials":1873,"activeCount":100},[1874,1886,1893],{"nctId":1875,"briefTitle":1876,"status":252,"phases":1877,"primaryCompletion":1878,"completion":1879,"start":1880,"enrollment":586,"conditions":1881,"interventions":1883},"NCT02679105","Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy",[89,90],"2016-10","2019-03","2015-05",[1882],"Rhinitis, Allergic",[1884,1885],"ALK Alutard birch or 5-grasses","ALK diluent",{"nctId":1887,"briefTitle":1888,"status":252,"phases":1889,"primaryCompletion":1635,"completion":1635,"start":621,"enrollment":672,"conditions":1890,"interventions":1891},"NCT02975479","Intralymphatic Immunotherapy in Increasing Doses, Substudy",[89,90],[1639],[1864,1892],"ALK Alutard SQ 5-grasses or ALK Alutard Birch",{"nctId":1894,"briefTitle":1895,"status":252,"phases":1896,"primaryCompletion":1897,"completion":254,"start":1898,"enrollment":1899,"conditions":1900,"interventions":1901},"NCT02423707","Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy",[89,90],"2015-11","2010-08",110,[1642],[1902,1864],"ALK Alutard Birch and\u002For 5-grasses",{"trials":1904,"activeCount":100},[],{"trials":1906,"activeCount":100},[],{"intervention":1045,"totalTrials":545,"cells":1908},{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1917,"PHASE3":1919,"PHASE4":1944,"NA":1946},{"trials":1910,"activeCount":100},[],{"trials":1912,"activeCount":100},[1913],{"nctId":1034,"briefTitle":1035,"status":252,"phases":1914,"primaryCompletion":556,"completion":556,"start":1037,"enrollment":11,"conditions":1915,"interventions":1916},[88],[1039,1040,1041,1042],[1044,1045,1027],{"trials":1918,"activeCount":100},[],{"trials":1920,"activeCount":100},[1921,1934],{"nctId":1922,"briefTitle":1923,"status":252,"phases":1924,"primaryCompletion":1925,"completion":1925,"start":1926,"enrollment":1927,"conditions":1928,"interventions":1933},"NCT01787110","An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction",[90],"2016-12-30","2013-04",6629,[1929,1930,1931,1932],"Acute Coronary Syndrome","Non-ST Elevation (NSTEMI) Myocardial Infarction","Acute ST Segment Elevation Myocardial Infarction","Angina, Unstable",[1045],{"nctId":1935,"briefTitle":1936,"status":252,"phases":1937,"primaryCompletion":556,"completion":556,"start":1037,"enrollment":1938,"conditions":1939,"interventions":1943},"NCT02290080","Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers",[90],175,[1940,1041,1941,1942,1930,1932],"Acute Myocardial Infarction (AMI)","ST Elevation (STEMI) Myocardial Infarction","Ischemic Reperfusion Injury",[1045],{"trials":1945,"activeCount":100},[],{"trials":1947,"activeCount":100},[],{"intervention":1884,"totalTrials":194,"cells":1949},{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1972,"NA":1974},{"trials":1951,"activeCount":100},[],{"trials":1953,"activeCount":100},[],{"trials":1955,"activeCount":100},[],{"trials":1957,"activeCount":100},[1958,1962],{"nctId":1875,"briefTitle":1876,"status":252,"phases":1959,"primaryCompletion":1878,"completion":1879,"start":1880,"enrollment":586,"conditions":1960,"interventions":1961},[89,90],[1882],[1884,1885],{"nctId":1963,"briefTitle":1964,"status":252,"phases":1965,"primaryCompletion":254,"completion":254,"start":1966,"enrollment":1967,"conditions":1968,"interventions":1970},"NCT03394508","The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma",[89,90],"2013-01",30,[1969,948,819],"Rhinitis",[1884,1971],"ALK diluent 0,3% human albumin",{"trials":1973,"activeCount":100},[],{"trials":1975,"activeCount":100},[],{"intervention":1977,"totalTrials":96,"cells":1978},"Interferon-alpha2b - 1 year",{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1983,"PHASE3":1985,"PHASE4":1999,"NA":2001},{"trials":1980,"activeCount":100},[],{"trials":1982,"activeCount":100},[],{"trials":1984,"activeCount":100},[],{"trials":1986,"activeCount":100},[1987],{"nctId":1988,"briefTitle":1989,"status":252,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1997},"NCT01259934","Nordic Adjuvant IFN Melanoma Trial",[90],"2008-06","1996-11",855,[1995,1996],"Melanoma","Adjuvant Therapy",[1977,1998],"Interferon-alpha2b - 2 years",{"trials":2000,"activeCount":100},[],{"trials":2002,"activeCount":100},[],{"intervention":1998,"totalTrials":96,"cells":2004},{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2009,"PHASE3":2011,"PHASE4":2017,"NA":2019},{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":100},[],{"trials":2012,"activeCount":100},[2013],{"nctId":1988,"briefTitle":1989,"status":252,"phases":2014,"primaryCompletion":1991,"completion":1991,"start":1992,"enrollment":1993,"conditions":2015,"interventions":2016},[90],[1995,1996],[1977,1998],{"trials":2018,"activeCount":100},[],{"trials":2020,"activeCount":100},[],{"intervention":2022,"totalTrials":96,"cells":2023},"Hyperbaric oxygen",{"EARLY_PHASE1":2024,"PHASE1":2026,"PHASE2":2028,"PHASE3":2030,"PHASE4":2048,"NA":2050},{"trials":2025,"activeCount":100},[],{"trials":2027,"activeCount":100},[],{"trials":2029,"activeCount":100},[],{"trials":2031,"activeCount":100},[2032],{"nctId":2033,"briefTitle":2034,"status":1457,"phases":2035,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2040,"interventions":2047},"NCT04327505","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19",[89,90],"2022-06-30","2022-12-01","2020-06-03",34,[2041,2042,2043,2044,2045,2046],"SARS (Severe Acute Respiratory Syndrome)","Cytokine Storm","ARDS, Human","COVID-19","Sars-CoV2","Acute Respiratory Failure",[2022],{"trials":2049,"activeCount":100},[],{"trials":2051,"activeCount":100},[],{"intervention":2053,"totalTrials":96,"cells":2054},"Oxygen gas",{"EARLY_PHASE1":2055,"PHASE1":2057,"PHASE2":2059,"PHASE3":2061,"PHASE4":2074,"NA":2076},{"trials":2056,"activeCount":100},[],{"trials":2058,"activeCount":100},[],{"trials":2060,"activeCount":100},[],{"trials":2062,"activeCount":100},[2063],{"nctId":2064,"briefTitle":2065,"status":1457,"phases":2066,"primaryCompletion":2067,"completion":2068,"start":2069,"enrollment":2070,"conditions":2071,"interventions":2073},"NCT03369184","Elective Percutaneous Coronary Intervention With or Without Supplemental OXYgen",[90],"2019-05-01","2020-08-01","2018-01-01",65,[2072],"Coronary Artery Disease",[2053],{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"intervention":2079,"totalTrials":96,"cells":2080},"Test of peritoneal fluid and solute transport using the relatvely new bicarbonate-lactate buffered peritoneal dialysis solution compared to convetional lactate based peritoneal dialysis solution",{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2087,"PHASE4":2100,"NA":2102},{"trials":2082,"activeCount":100},[],{"trials":2084,"activeCount":100},[],{"trials":2086,"activeCount":100},[],{"trials":2088,"activeCount":100},[2089],{"nctId":2090,"briefTitle":2091,"status":252,"phases":2092,"primaryCompletion":2093,"completion":2093,"start":2094,"enrollment":2095,"conditions":2096,"interventions":2099},"NCT07621627","Peritoneal Transport With a New Bicarbonate-based Peritoneal Dialysis Solution Compared to Conventional Solution.",[90],"1997-11-13","1997-09-09",7,[2097,2098],"Chronic Renal Failure (CRF)","Dialysis Dependent Chronic Kidney Disease",[2079],{"trials":2101,"activeCount":100},[],{"trials":2103,"activeCount":100},[],{"intervention":2105,"totalTrials":96,"cells":2106},"Sirolimus\u002Ftacrolimus",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2113,"PHASE4":2126,"NA":2128},{"trials":2108,"activeCount":100},[],{"trials":2110,"activeCount":100},[],{"trials":2112,"activeCount":100},[],{"trials":2114,"activeCount":100},[2115],{"nctId":2116,"briefTitle":2117,"status":252,"phases":2118,"primaryCompletion":1344,"completion":1345,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2124},"NCT00993343","Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation",[90],"2007-09",215,[2122,2123],"Graft-versus-host Disease","Survival",[2105,2125],"cyclosporine\u002Fmethotrexate",{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":100},[],{"intervention":2125,"totalTrials":96,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2144,"NA":2146},{"trials":2133,"activeCount":100},[],{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":100},[],{"trials":2139,"activeCount":100},[2140],{"nctId":2116,"briefTitle":2117,"status":252,"phases":2141,"primaryCompletion":1344,"completion":1345,"start":2119,"enrollment":2120,"conditions":2142,"interventions":2143},[90],[2122,2123],[2105,2125],{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":100},[],{"intervention":2149,"totalTrials":96,"cells":2150},"Anakinra",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2170,"NA":2172},{"trials":2152,"activeCount":100},[],{"trials":2154,"activeCount":100},[],{"trials":2156,"activeCount":100},[],{"trials":2158,"activeCount":100},[2159],{"nctId":2160,"briefTitle":2161,"status":252,"phases":2162,"completion":2163,"start":2164,"conditions":2165,"interventions":2169},"NCT01165008","Anakinra in Myositis",[89,90],"2008-09","2003-09",[2166,2167,2168],"Polymyositis","Dermatomyositis","Inclusion Body Myositis",[2149],{"trials":2171,"activeCount":100},[],{"trials":2173,"activeCount":100},[],{"intervention":626,"totalTrials":96,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":100},[],{"trials":2179,"activeCount":100},[],{"trials":2181,"activeCount":100},[],{"trials":2183,"activeCount":100},[2184],{"nctId":617,"briefTitle":618,"status":252,"phases":2185,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":2186,"interventions":2187},[90],[624],[597,626],{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":100},[],{"intervention":2193,"totalTrials":96,"cells":2194},"Fluoxetine",{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2199,"PHASE3":2201,"PHASE4":2212,"NA":2214},{"trials":2196,"activeCount":100},[],{"trials":2198,"activeCount":100},[],{"trials":2200,"activeCount":100},[],{"trials":2202,"activeCount":100},[2203],{"nctId":2204,"briefTitle":2205,"status":252,"phases":2206,"primaryCompletion":2207,"completion":2207,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2211},"NCT02683213","Efficacy of Fluoxetine - a Trial in Stroke",[90],"2020-06","2014-10-20",1500,[21],[2193],{"trials":2213,"activeCount":100},[],{"trials":2215,"activeCount":100},[],{"intervention":1892,"totalTrials":96,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2230,"NA":2232},{"trials":2219,"activeCount":100},[],{"trials":2221,"activeCount":100},[],{"trials":2223,"activeCount":100},[],{"trials":2225,"activeCount":100},[2226],{"nctId":1887,"briefTitle":1888,"status":252,"phases":2227,"primaryCompletion":1635,"completion":1635,"start":621,"enrollment":672,"conditions":2228,"interventions":2229},[89,90],[1639],[1864,1892],{"trials":2231,"activeCount":100},[],{"trials":2233,"activeCount":100},[],{"intervention":2235,"totalTrials":96,"cells":2236},"Transdermal testosterone therapy",{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2254,"NA":2256},{"trials":2238,"activeCount":100},[],{"trials":2240,"activeCount":100},[],{"trials":2242,"activeCount":100},[],{"trials":2244,"activeCount":100},[2245],{"nctId":2246,"briefTitle":2247,"status":568,"phases":2248,"primaryCompletion":1056,"completion":2249,"start":1555,"enrollment":2250,"conditions":2251,"interventions":2253},"NCT00479609","Testosterone Therapy in Men With Low Testosterone Levels and Metabolic Syndrome or Early Stages of Type 2 Diabetes",[90],"2009-04",176,[2252],"Metabolic Syndrome",[2235],{"trials":2255,"activeCount":100},[],{"trials":2257,"activeCount":100},[],{"intervention":2259,"totalTrials":96,"cells":2260},"Dexamethasone",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2267,"PHASE4":2281,"NA":2283},{"trials":2262,"activeCount":100},[],{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"trials":2268,"activeCount":100},[2269],{"nctId":2270,"briefTitle":2271,"status":252,"phases":2272,"primaryCompletion":2273,"completion":2274,"start":2275,"enrollment":2276,"conditions":2277,"interventions":2280},"NCT05195242","The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19",[90],"2021-06-20","2021-06-30","2020-08-27",445,[2044,2278,2279],"Thrombosis Embolism","Bleeding",[2259],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"intervention":2286,"totalTrials":96,"cells":2287},"Bupivacaine",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2307,"NA":2309},{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":100},[2296],{"nctId":2297,"briefTitle":2298,"status":252,"phases":2299,"primaryCompletion":2300,"completion":2300,"start":2301,"enrollment":2302,"conditions":2303,"interventions":2305},"NCT03639389","Postoperative Pain, Recovery and Discharge Following Robot-assisted Laparoscopic Prostatectomy",[90],"2022-03-29","2019-01-01",211,[2304,225],"Radical Prostatectomy",[2286,2306],"Analgesics",{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[],{"intervention":2306,"totalTrials":96,"cells":2312},{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2317,"PHASE3":2319,"PHASE4":2325,"NA":2327},{"trials":2314,"activeCount":100},[],{"trials":2316,"activeCount":100},[],{"trials":2318,"activeCount":100},[],{"trials":2320,"activeCount":100},[2321],{"nctId":2297,"briefTitle":2298,"status":252,"phases":2322,"primaryCompletion":2300,"completion":2300,"start":2301,"enrollment":2302,"conditions":2323,"interventions":2324},[90],[2304,225],[2286,2306],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"intervention":2330,"totalTrials":96,"cells":2331},"Mepivacaine",{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2338,"PHASE4":2350,"NA":2352},{"trials":2333,"activeCount":100},[],{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[],{"trials":2339,"activeCount":100},[2340],{"nctId":2341,"briefTitle":2342,"status":252,"phases":2343,"primaryCompletion":2344,"completion":2344,"start":2345,"enrollment":2346,"conditions":2347,"interventions":2349},"NCT02078063","Analgesia for Insertion of Intrauterine Contraception",[90],"2017-11","2013-11",86,[2348],"Insertion of Intrauterine Contraception",[2330],{"trials":2351,"activeCount":100},[],{"trials":2353,"activeCount":100},[],{"intervention":1902,"totalTrials":96,"cells":2355},{"EARLY_PHASE1":2356,"PHASE1":2358,"PHASE2":2360,"PHASE3":2362,"PHASE4":2368,"NA":2370},{"trials":2357,"activeCount":100},[],{"trials":2359,"activeCount":100},[],{"trials":2361,"activeCount":100},[],{"trials":2363,"activeCount":100},[2364],{"nctId":1894,"briefTitle":1895,"status":252,"phases":2365,"primaryCompletion":1897,"completion":254,"start":1898,"enrollment":1899,"conditions":2366,"interventions":2367},[89,90],[1642],[1902,1864],{"trials":2369,"activeCount":100},[],{"trials":2371,"activeCount":100},[],{"intervention":1971,"totalTrials":96,"cells":2373},{"EARLY_PHASE1":2374,"PHASE1":2376,"PHASE2":2378,"PHASE3":2380,"PHASE4":2386,"NA":2388},{"trials":2375,"activeCount":100},[],{"trials":2377,"activeCount":100},[],{"trials":2379,"activeCount":100},[],{"trials":2381,"activeCount":100},[2382],{"nctId":1963,"briefTitle":1964,"status":252,"phases":2383,"primaryCompletion":254,"completion":254,"start":1966,"enrollment":1967,"conditions":2384,"interventions":2385},[89,90],[1969,948,819],[1884,1971],{"trials":2387,"activeCount":100},[],{"trials":2389,"activeCount":100},[],{"intervention":261,"totalTrials":96,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2404,"NA":2406},{"trials":2393,"activeCount":100},[],{"trials":2395,"activeCount":100},[],{"trials":2397,"activeCount":100},[],{"trials":2399,"activeCount":100},[2400],{"nctId":250,"briefTitle":251,"status":252,"phases":2401,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":2402,"interventions":2403},[90],[259],[261,262],{"trials":2405,"activeCount":100},[],{"trials":2407,"activeCount":100},[],{"intervention":2409,"totalTrials":96,"cells":2410},"Irbesartan",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2429,"NA":2431},{"trials":2412,"activeCount":100},[],{"trials":2414,"activeCount":100},[],{"trials":2416,"activeCount":100},[],{"trials":2418,"activeCount":100},[2419],{"nctId":2420,"briefTitle":2421,"status":252,"phases":2422,"primaryCompletion":2423,"completion":2423,"start":2424,"enrollment":2425,"conditions":2426,"interventions":2427},"NCT00389168","Irbesartan and Atenolol in Hypertensive Heart Disease",[89,90],"1997-04","1995-04",115,[1348],[2409,2428],"Atenolol",{"trials":2430,"activeCount":100},[],{"trials":2432,"activeCount":100},[],{"intervention":2428,"totalTrials":96,"cells":2434},{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2447,"NA":2449},{"trials":2436,"activeCount":100},[],{"trials":2438,"activeCount":100},[],{"trials":2440,"activeCount":100},[],{"trials":2442,"activeCount":100},[2443],{"nctId":2420,"briefTitle":2421,"status":252,"phases":2444,"primaryCompletion":2423,"completion":2423,"start":2424,"enrollment":2425,"conditions":2445,"interventions":2446},[89,90],[1348],[2409,2428],{"trials":2448,"activeCount":100},[],{"trials":2450,"activeCount":100},[],{"intervention":2452,"totalTrials":194,"cells":2453},"Autologous mesenchymal stem cells",{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2469,"PHASE3":2480,"PHASE4":2482,"NA":2484},{"trials":2455,"activeCount":100},[],{"trials":2457,"activeCount":100},[2458],{"nctId":2459,"briefTitle":2460,"status":252,"phases":2461,"primaryCompletion":2462,"completion":2463,"start":2464,"enrollment":2095,"conditions":2465,"interventions":2468},"NCT03778333","Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden",[88],"2016-12","2016-12-31","2012-12-01",[2466,2467],"Autologous Mesenchymal Stem Cells","Multiple Sclerosis",[2452],{"trials":2470,"activeCount":100},[2471],{"nctId":2472,"briefTitle":2473,"status":252,"phases":2474,"primaryCompletion":2475,"completion":2476,"start":2477,"enrollment":194,"conditions":2478,"interventions":2479},"NCT01730547","Mesenchymal Stem Cells for Multiple Sclerosis",[88,89],"2019-05-09","2021-11-20","2013-02",[2467],[2452],{"trials":2481,"activeCount":100},[],{"trials":2483,"activeCount":100},[],{"trials":2485,"activeCount":100},[],{"intervention":2487,"totalTrials":194,"cells":2488},"vitamin D",{"EARLY_PHASE1":2489,"PHASE1":2491,"PHASE2":2493,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2490,"activeCount":100},[],{"trials":2492,"activeCount":100},[],{"trials":2494,"activeCount":100},[2495,2505],{"nctId":2496,"briefTitle":2497,"status":252,"phases":2498,"primaryCompletion":2499,"completion":2499,"start":2500,"enrollment":2501,"conditions":2502,"interventions":2504},"NCT01698476","Immune Reconstitution in Tuberculosis Disease",[89],"2015-08","2012-09",390,[2503],"Pulmonary Tuberculosis (TB)",[2487],{"nctId":2506,"briefTitle":2507,"status":252,"phases":2508,"primaryCompletion":2499,"completion":2499,"start":2500,"enrollment":2509,"conditions":2510,"interventions":2512},"NCT01702974","Immune Reconstitution in HIV Disease (IREHIV)",[89],279,[2511],"HIV Infection",[2487],{"trials":2514,"activeCount":100},[],{"trials":2516,"activeCount":100},[],{"trials":2518,"activeCount":100},[],{"intervention":2520,"totalTrials":194,"cells":2521},"Mesenchymal stromal cells",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2537,"PHASE3":2548,"PHASE4":2550,"NA":2552},{"trials":2523,"activeCount":100},[],{"trials":2525,"activeCount":100},[2526],{"nctId":2527,"briefTitle":2528,"status":1457,"phases":2529,"primaryCompletion":2530,"completion":2531,"start":2532,"enrollment":2533,"conditions":2534,"interventions":2536},"NCT01522716","Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease",[88],"2016-03","2017-03","2011-08",11,[2535],"Graft-Versus-Host Disease",[2520],{"trials":2538,"activeCount":100},[2539],{"nctId":2540,"briefTitle":2541,"status":218,"phases":2542,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":100,"conditions":2545,"interventions":2547},"NCT02055625","Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease",[88,89],"2019-08","2014-01",[2546],"Graft -Versus-host-disease",[2520],{"trials":2549,"activeCount":100},[],{"trials":2551,"activeCount":100},[],{"trials":2553,"activeCount":100},[],{"intervention":2555,"totalTrials":194,"cells":2556},"Decidual stromal cell therapy",{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2583,"PHASE4":2585,"NA":2587},{"trials":2558,"activeCount":100},[],{"trials":2560,"activeCount":100},[],{"trials":2562,"activeCount":100},[2563,2573],{"nctId":2564,"briefTitle":2565,"status":568,"phases":2566,"primaryCompletion":254,"completion":254,"start":2567,"enrollment":1098,"conditions":2568,"interventions":2572},"NCT02175303","A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting",[88,89],"2013-12",[2569,2570,2571,1040],"Acute Lung Injury","Decidual Stromal Cells","Stem Cell Transplantation",[2555],{"nctId":2574,"briefTitle":2575,"status":252,"phases":2576,"primaryCompletion":2567,"completion":2567,"start":2577,"enrollment":2578,"conditions":2579,"interventions":2581},"NCT02172963","A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis",[88,89],"2011-11",12,[2580],"Hemorrhagic Cystitis",[2582],"Decidual Stromal Cell therapy",{"trials":2584,"activeCount":100},[],{"trials":2586,"activeCount":100},[],{"trials":2588,"activeCount":100},[],{"intervention":2590,"totalTrials":96,"cells":2591},"Bosentan",{"EARLY_PHASE1":2592,"PHASE1":2594,"PHASE2":2596,"PHASE3":2607,"PHASE4":2609,"NA":2611},{"trials":2593,"activeCount":100},[],{"trials":2595,"activeCount":100},[],{"trials":2597,"activeCount":100},[2598],{"nctId":2599,"briefTitle":2600,"status":252,"phases":2601,"primaryCompletion":1795,"completion":2602,"start":2603,"enrollment":2604,"conditions":2605,"interventions":2606},"NCT01357109","Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes",[89],"2011-01","2007-11",56,[1168],[2590],{"trials":2608,"activeCount":100},[],{"trials":2610,"activeCount":100},[],{"trials":2612,"activeCount":100},[],{"intervention":2614,"totalTrials":96,"cells":2615},"Early Decidual stromal cell therapy",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2617,"activeCount":100},[],{"trials":2619,"activeCount":100},[],{"trials":2621,"activeCount":100},[2622],{"nctId":2623,"briefTitle":2624,"status":568,"phases":2625,"primaryCompletion":2626,"completion":2626,"start":2627,"enrollment":1967,"conditions":2628,"interventions":2630},"NCT02172924","A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease",[88,89],"2019-12","2017-01",[2629],"Graft vs Host Disease",[2614,2631],"Late Decidual stromal cell therapy",{"trials":2633,"activeCount":100},[],{"trials":2635,"activeCount":100},[],{"trials":2637,"activeCount":100},[],{"intervention":2631,"totalTrials":96,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2650,"PHASE4":2652,"NA":2654},{"trials":2641,"activeCount":100},[],{"trials":2643,"activeCount":100},[],{"trials":2645,"activeCount":100},[2646],{"nctId":2623,"briefTitle":2624,"status":568,"phases":2647,"primaryCompletion":2626,"completion":2626,"start":2627,"enrollment":1967,"conditions":2648,"interventions":2649},[88,89],[2629],[2614,2631],{"trials":2651,"activeCount":100},[],{"trials":2653,"activeCount":100},[],{"trials":2655,"activeCount":100},[],{"intervention":2657,"totalTrials":96,"cells":2658},"Sirolimus",{"EARLY_PHASE1":2659,"PHASE1":2661,"PHASE2":2663,"PHASE3":2675,"PHASE4":2677,"NA":2679},{"trials":2660,"activeCount":100},[],{"trials":2662,"activeCount":100},[],{"trials":2664,"activeCount":100},[2665],{"nctId":2666,"briefTitle":2667,"status":252,"phases":2668,"primaryCompletion":2669,"completion":2670,"start":2671,"enrollment":29,"conditions":2672,"interventions":2674},"NCT06022068","Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography",[88,89],"2024-12-11","2025-01-17","2023-09-01",[2673],"Alzheimer Disease",[2657],{"trials":2676,"activeCount":100},[],{"trials":2678,"activeCount":100},[],{"trials":2680,"activeCount":100},[],{"intervention":2682,"totalTrials":96,"cells":2683},"Misoprostol sublingual, 1h",{"EARLY_PHASE1":2684,"PHASE1":2686,"PHASE2":2688,"PHASE3":2704,"PHASE4":2706,"NA":2708},{"trials":2685,"activeCount":100},[],{"trials":2687,"activeCount":100},[],{"trials":2689,"activeCount":100},[2690],{"nctId":2691,"briefTitle":2692,"status":252,"phases":2693,"primaryCompletion":2694,"completion":2694,"start":2695,"enrollment":2696,"conditions":2697,"interventions":2700},"NCT01933360","Misoprostol for Cervical Priming Prior to Vacuum Aspiration",[89],"2014-03","2013-08",184,[2698,2699],"First Trimester Pregnancy","Surgical Termination of Pregnancy",[2682,2701,2702,2703],"Misoprostol sublingual, 3h","Misoprostol vaginal, 1h","Misoprostol vaginal, 3h",{"trials":2705,"activeCount":100},[],{"trials":2707,"activeCount":100},[],{"trials":2709,"activeCount":100},[],{"intervention":2701,"totalTrials":96,"cells":2711},{"EARLY_PHASE1":2712,"PHASE1":2714,"PHASE2":2716,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2713,"activeCount":100},[],{"trials":2715,"activeCount":100},[],{"trials":2717,"activeCount":100},[2718],{"nctId":2691,"briefTitle":2692,"status":252,"phases":2719,"primaryCompletion":2694,"completion":2694,"start":2695,"enrollment":2696,"conditions":2720,"interventions":2721},[89],[2698,2699],[2682,2701,2702,2703],{"trials":2723,"activeCount":100},[],{"trials":2725,"activeCount":100},[],{"trials":2727,"activeCount":100},[],{"intervention":2702,"totalTrials":96,"cells":2729},{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2734,"PHASE3":2740,"PHASE4":2742,"NA":2744},{"trials":2731,"activeCount":100},[],{"trials":2733,"activeCount":100},[],{"trials":2735,"activeCount":100},[2736],{"nctId":2691,"briefTitle":2692,"status":252,"phases":2737,"primaryCompletion":2694,"completion":2694,"start":2695,"enrollment":2696,"conditions":2738,"interventions":2739},[89],[2698,2699],[2682,2701,2702,2703],{"trials":2741,"activeCount":100},[],{"trials":2743,"activeCount":100},[],{"trials":2745,"activeCount":100},[],{"intervention":2703,"totalTrials":96,"cells":2747},{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2752,"PHASE3":2758,"PHASE4":2760,"NA":2762},{"trials":2749,"activeCount":100},[],{"trials":2751,"activeCount":100},[],{"trials":2753,"activeCount":100},[2754],{"nctId":2691,"briefTitle":2692,"status":252,"phases":2755,"primaryCompletion":2694,"completion":2694,"start":2695,"enrollment":2696,"conditions":2756,"interventions":2757},[89],[2698,2699],[2682,2701,2702,2703],{"trials":2759,"activeCount":100},[],{"trials":2761,"activeCount":100},[],{"trials":2763,"activeCount":100},[],{"intervention":2765,"totalTrials":96,"cells":2766},"Ibuprofen",{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2783,"PHASE4":2785,"NA":2787},{"trials":2768,"activeCount":100},[],{"trials":2770,"activeCount":100},[],{"trials":2772,"activeCount":100},[2773],{"nctId":2774,"briefTitle":2775,"status":252,"phases":2776,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":2039,"conditions":2779,"interventions":2781},"NCT02531451","The Effects of COX-inhibiting Drugs on Skeletal Muscle Adaptations to Resistance Exercise in Healthy Adults",[89],"2016-06","2015-09",[2780],"Skeletal Muscle Mass Regulation",[2765,2782],"Acetylsalicylic acid",{"trials":2784,"activeCount":100},[],{"trials":2786,"activeCount":100},[],{"trials":2788,"activeCount":100},[],{"intervention":2782,"totalTrials":96,"cells":2790},{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2795,"PHASE3":2801,"PHASE4":2803,"NA":2805},{"trials":2792,"activeCount":100},[],{"trials":2794,"activeCount":100},[],{"trials":2796,"activeCount":100},[2797],{"nctId":2774,"briefTitle":2775,"status":252,"phases":2798,"primaryCompletion":2777,"completion":2777,"start":2778,"enrollment":2039,"conditions":2799,"interventions":2800},[89],[2780],[2765,2782],{"trials":2802,"activeCount":100},[],{"trials":2804,"activeCount":100},[],{"trials":2806,"activeCount":100},[],{"intervention":2808,"totalTrials":96,"cells":2809},"Mifepristone prior to Mirena",{"EARLY_PHASE1":2810,"PHASE1":2812,"PHASE2":2814,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2811,"activeCount":100},[],{"trials":2813,"activeCount":100},[],{"trials":2815,"activeCount":100},[2816],{"nctId":2817,"briefTitle":2818,"status":252,"phases":2819,"primaryCompletion":556,"completion":556,"start":2695,"enrollment":864,"conditions":2820,"interventions":2822},"NCT01931657","Pretreatment With Mifepristone Prior to Mirena Insertion",[89],[2821],"Women in Need of Long Acting Reversibel Cntraception With the Intrauterine Levonorgestrel Releasing System, Mirena",[2808],{"trials":2824,"activeCount":100},[],{"trials":2826,"activeCount":100},[],{"trials":2828,"activeCount":100},[],{"intervention":2830,"totalTrials":96,"cells":2831},"Chlorhexidine Gluconate",{"EARLY_PHASE1":2832,"PHASE1":2834,"PHASE2":2836,"PHASE3":2848,"PHASE4":2850,"NA":2852},{"trials":2833,"activeCount":100},[],{"trials":2835,"activeCount":100},[],{"trials":2837,"activeCount":100},[2838],{"nctId":2839,"briefTitle":2840,"status":568,"phases":2841,"primaryCompletion":2842,"completion":1683,"start":2843,"enrollment":864,"conditions":2844,"interventions":2846},"NCT05059145","A Clinical Trial for Chlorhexidine as Treatment for Vulvovaginal Candidiasis",[89],"2024-12-31","2022-04-27",[2845],"Candidiasis, Vulvovaginal",[2830,2847],"Fluconazole",{"trials":2849,"activeCount":100},[],{"trials":2851,"activeCount":100},[],{"trials":2853,"activeCount":100},[],{"intervention":2847,"totalTrials":96,"cells":2855},{"EARLY_PHASE1":2856,"PHASE1":2858,"PHASE2":2860,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2857,"activeCount":100},[],{"trials":2859,"activeCount":100},[],{"trials":2861,"activeCount":100},[2862],{"nctId":2839,"briefTitle":2840,"status":568,"phases":2863,"primaryCompletion":2842,"completion":1683,"start":2843,"enrollment":864,"conditions":2864,"interventions":2865},[89],[2845],[2830,2847],{"trials":2867,"activeCount":100},[],{"trials":2869,"activeCount":100},[],{"trials":2871,"activeCount":100},[],{"intervention":2873,"totalTrials":96,"cells":2874},"Tamoxifen",{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2876,"activeCount":100},[],{"trials":2878,"activeCount":100},[],{"trials":2880,"activeCount":100},[2881],{"nctId":2882,"briefTitle":2883,"status":252,"phases":2884,"primaryCompletion":2885,"completion":2530,"start":2886,"enrollment":2887,"conditions":2888,"interventions":2890},"NCT04079517","Karolinska Interventional Study of Mammograhic Density (Karisma-1)",[88,89],"2016-02","2015-03",42,[285,2889],"Mammographic Density",[2873],{"trials":2892,"activeCount":100},[],{"trials":2894,"activeCount":100},[],{"trials":2896,"activeCount":100},[],{"intervention":2898,"totalTrials":96,"cells":2899},"Decidual Stromal Cells thawed in plasma",{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2904,"PHASE3":2913,"PHASE4":2915,"NA":2917},{"trials":2901,"activeCount":100},[],{"trials":2903,"activeCount":100},[],{"trials":2905,"activeCount":100},[2906],{"nctId":2907,"briefTitle":2908,"status":568,"phases":2909,"primaryCompletion":2462,"completion":2462,"start":2602,"enrollment":609,"conditions":2910,"interventions":2911},"NCT02172937","Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study",[88,89],[2629],[2898,2912],"Decidual Stromal Cells thawed in human albumin",{"trials":2914,"activeCount":100},[],{"trials":2916,"activeCount":100},[],{"trials":2918,"activeCount":100},[],{"intervention":2912,"totalTrials":96,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2922,"activeCount":100},[],{"trials":2924,"activeCount":100},[],{"trials":2926,"activeCount":100},[2927],{"nctId":2907,"briefTitle":2908,"status":568,"phases":2928,"primaryCompletion":2462,"completion":2462,"start":2602,"enrollment":609,"conditions":2929,"interventions":2930},[88,89],[2629],[2898,2912],{"trials":2932,"activeCount":100},[],{"trials":2934,"activeCount":100},[],{"trials":2936,"activeCount":100},[],{"intervention":2938,"totalTrials":96,"cells":2939},"Sevoflurane",{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2941,"activeCount":100},[],{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[2946],{"nctId":2947,"briefTitle":2948,"status":252,"phases":2949,"primaryCompletion":1205,"completion":1556,"start":2950,"enrollment":257,"conditions":2951,"interventions":2953},"NCT00484575","Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting",[88,89],"2007-06",[2952,28],"Myocardial Reperfusion Injury",[2938,2954],"propofol",{"trials":2956,"activeCount":100},[],{"trials":2958,"activeCount":100},[],{"trials":2960,"activeCount":100},[],{"intervention":2954,"totalTrials":96,"cells":2962},{"EARLY_PHASE1":2963,"PHASE1":2965,"PHASE2":2967,"PHASE3":2973,"PHASE4":2975,"NA":2977},{"trials":2964,"activeCount":100},[],{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[2969],{"nctId":2947,"briefTitle":2948,"status":252,"phases":2970,"primaryCompletion":1205,"completion":1556,"start":2950,"enrollment":257,"conditions":2971,"interventions":2972},[88,89],[2952,28],[2938,2954],{"trials":2974,"activeCount":100},[],{"trials":2976,"activeCount":100},[],{"trials":2978,"activeCount":100},[],{"intervention":2980,"totalTrials":96,"cells":2981},"Decidual stromal cells",{"EARLY_PHASE1":2982,"PHASE1":2984,"PHASE2":2986,"PHASE3":2994,"PHASE4":2996,"NA":2998},{"trials":2983,"activeCount":100},[],{"trials":2985,"activeCount":100},[],{"trials":2987,"activeCount":100},[2988],{"nctId":2989,"briefTitle":2990,"status":568,"phases":2991,"primaryCompletion":2462,"completion":2462,"start":2694,"enrollment":19,"conditions":2992,"interventions":2993},"NCT02174536","A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis",[89],[2580,2571,2570],[2980],{"trials":2995,"activeCount":100},[],{"trials":2997,"activeCount":100},[],{"trials":2999,"activeCount":100},[],{"intervention":3001,"totalTrials":96,"cells":3002},"Abatacept Active Treatment",{"EARLY_PHASE1":3003,"PHASE1":3005,"PHASE2":3007,"PHASE3":3017,"PHASE4":3019,"NA":3021},{"trials":3004,"activeCount":100},[],{"trials":3006,"activeCount":100},[],{"trials":3008,"activeCount":100},[3009],{"nctId":3010,"briefTitle":3011,"status":252,"phases":3012,"primaryCompletion":3013,"completion":3013,"start":2602,"enrollment":19,"conditions":3014,"interventions":3015},"NCT01315938","Abatacept Treatment in Polymyositis and Dermatomyositis",[89],"2013-11-28",[2166,2167],[3001,3016],"Abatacept Delayed-Onset Treatment",{"trials":3018,"activeCount":100},[],{"trials":3020,"activeCount":100},[],{"trials":3022,"activeCount":100},[],{"intervention":3016,"totalTrials":96,"cells":3024},{"EARLY_PHASE1":3025,"PHASE1":3027,"PHASE2":3029,"PHASE3":3035,"PHASE4":3037,"NA":3039},{"trials":3026,"activeCount":100},[],{"trials":3028,"activeCount":100},[],{"trials":3030,"activeCount":100},[3031],{"nctId":3010,"briefTitle":3011,"status":252,"phases":3032,"primaryCompletion":3013,"completion":3013,"start":2602,"enrollment":19,"conditions":3033,"interventions":3034},[89],[2166,2167],[3001,3016],{"trials":3036,"activeCount":100},[],{"trials":3038,"activeCount":100},[],{"trials":3040,"activeCount":100},[],{"intervention":3042,"totalTrials":96,"cells":3043},"Nirmatrelvir\u002Fritonavir",{"EARLY_PHASE1":3044,"PHASE1":3046,"PHASE2":3048,"PHASE3":3068,"PHASE4":3070,"NA":3072},{"trials":3045,"activeCount":100},[],{"trials":3047,"activeCount":100},[],{"trials":3049,"activeCount":100},[3050],{"nctId":3051,"briefTitle":3052,"status":252,"phases":3053,"primaryCompletion":3054,"completion":3054,"start":3055,"enrollment":3056,"conditions":3057,"interventions":3067},"NCT05823896","ImPROving Quality of LIFe in the Long COVID Patient",[89],"2024-11-28","2023-05-01",219,[3058,3059,3060,2044,3061,3062,3063,3064,3065,3066],"Post-COVID-19 Syndrome","Long COVID","Long Covid19","POTS - Postural Orthostatic Tachycardia Syndrome","Post COVID-19 Condition","Post-COVID Syndrome","Post COVID-19 Condition, Unspecified","Postinfectious Inflammation","Postinfectious Disorder",[3042],{"trials":3069,"activeCount":100},[],{"trials":3071,"activeCount":100},[],{"trials":3073,"activeCount":100},[],{"intervention":3075,"totalTrials":96,"cells":3076},"Oxytocin nasal spray",{"EARLY_PHASE1":3077,"PHASE1":3079,"PHASE2":3081,"PHASE3":3093,"PHASE4":3095,"NA":3097},{"trials":3078,"activeCount":100},[],{"trials":3080,"activeCount":100},[],{"trials":3082,"activeCount":100},[3083],{"nctId":3084,"briefTitle":3085,"status":1457,"phases":3086,"primaryCompletion":3087,"completion":3087,"start":3088,"enrollment":3089,"conditions":3090,"interventions":3092},"NCT06199076","Experimental Study on Alcohol Use and Behavior in Young Adults",[89],"2025-04-23","2023-10-17",206,[3091],"Alcohol Use Disorder",[3075],{"trials":3094,"activeCount":100},[],{"trials":3096,"activeCount":100},[],{"trials":3098,"activeCount":100},[],{"intervention":3100,"totalTrials":96,"cells":3101},"Melatonin 10 mg",{"EARLY_PHASE1":3102,"PHASE1":3104,"PHASE2":3106,"PHASE3":3119,"PHASE4":3121,"NA":3123},{"trials":3103,"activeCount":100},[],{"trials":3105,"activeCount":100},[],{"trials":3107,"activeCount":100},[3108],{"nctId":3109,"briefTitle":3110,"status":252,"phases":3111,"primaryCompletion":3112,"completion":2274,"start":3113,"enrollment":1409,"conditions":3114,"interventions":3117},"NCT03782740","Effect of Melatonin on Reduction of Pelvic Pain",[89],"2021-06-27","2019-03-15",[3115,3116],"Dysmenorrhea","Endometriosis",[3100,3118],"Melatonin 20 mg",{"trials":3120,"activeCount":100},[],{"trials":3122,"activeCount":100},[],{"trials":3124,"activeCount":100},[],{"intervention":3118,"totalTrials":96,"cells":3126},{"EARLY_PHASE1":3127,"PHASE1":3129,"PHASE2":3131,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3128,"activeCount":100},[],{"trials":3130,"activeCount":100},[],{"trials":3132,"activeCount":100},[3133],{"nctId":3109,"briefTitle":3110,"status":252,"phases":3134,"primaryCompletion":3112,"completion":2274,"start":3113,"enrollment":1409,"conditions":3135,"interventions":3136},[89],[3115,3116],[3100,3118],{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":100},[],{"intervention":3144,"totalTrials":96,"cells":3145},"Escitalopram",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3160,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3147,"activeCount":100},[],{"trials":3149,"activeCount":100},[3150],{"nctId":3151,"briefTitle":3152,"status":252,"phases":3153,"primaryCompletion":1176,"completion":3154,"start":3155,"enrollment":3156,"conditions":3157,"interventions":3159},"NCT01638689","A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram",[88],"2012-07","2010-09",10,[3158],"Healthy",[3144],{"trials":3161,"activeCount":100},[],{"trials":3163,"activeCount":100},[],{"trials":3165,"activeCount":100},[],{"trials":3167,"activeCount":100},[],{"intervention":3169,"totalTrials":96,"cells":3170},"calcium lactate solution",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3185,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3172,"activeCount":100},[],{"trials":3174,"activeCount":100},[3175],{"nctId":3176,"briefTitle":3177,"status":252,"phases":3178,"primaryCompletion":3179,"completion":2500,"start":3180,"enrollment":3181,"conditions":3182,"interventions":3184},"NCT01473537","Optimised Fluoride Prevention by Double Rinse With Fluoride and Calcium",[88],"2012-03","2011-10",9,[3183],"Dental Caries",[3169],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":100},[],{"trials":3190,"activeCount":100},[],{"trials":3192,"activeCount":100},[],{"intervention":3194,"totalTrials":96,"cells":3195},"N-pVAX1",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3209,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3197,"activeCount":100},[],{"trials":3199,"activeCount":100},[3200],{"nctId":3201,"briefTitle":3202,"status":252,"phases":3203,"primaryCompletion":3204,"completion":3204,"start":3205,"enrollment":24,"conditions":3206,"interventions":3208},"NCT06684431","Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever",[88],"2026-03-17","2024-11-12",[3207],"Crimean Congo Hemorrhagic Fever",[3194],{"trials":3210,"activeCount":100},[],{"trials":3212,"activeCount":100},[],{"trials":3214,"activeCount":100},[],{"trials":3216,"activeCount":100},[],{"intervention":3218,"totalTrials":96,"cells":3219},"N-hydroxy-nor-arginine",{"EARLY_PHASE1":3220,"PHASE1":3222,"PHASE2":3231,"PHASE3":3233,"PHASE4":3235,"NA":3237},{"trials":3221,"activeCount":100},[],{"trials":3223,"activeCount":100},[3224],{"nctId":3225,"briefTitle":3226,"status":252,"phases":3227,"primaryCompletion":1926,"completion":1002,"start":1318,"enrollment":1293,"conditions":3228,"interventions":3229},"NCT02009527","Arginase Inhibition in Ischemia-reperfusion Injury",[88],[2072,1168],[3218,3230],"NaCl",{"trials":3232,"activeCount":100},[],{"trials":3234,"activeCount":100},[],{"trials":3236,"activeCount":100},[],{"trials":3238,"activeCount":100},[],{"intervention":1044,"totalTrials":96,"cells":3240},{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3249,"PHASE3":3251,"PHASE4":3253,"NA":3255},{"trials":3242,"activeCount":100},[],{"trials":3244,"activeCount":100},[3245],{"nctId":1034,"briefTitle":1035,"status":252,"phases":3246,"primaryCompletion":556,"completion":556,"start":1037,"enrollment":11,"conditions":3247,"interventions":3248},[88],[1039,1040,1041,1042],[1044,1045,1027],{"trials":3250,"activeCount":100},[],{"trials":3252,"activeCount":100},[],{"trials":3254,"activeCount":100},[],{"trials":3256,"activeCount":100},[],{"intervention":3258,"totalTrials":96,"cells":3259},"fluvoxamine",{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3261,"activeCount":100},[],{"trials":3263,"activeCount":100},[3264],{"nctId":3265,"briefTitle":3266,"status":252,"phases":3267,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":29,"conditions":3270,"interventions":3271},"NCT01704638","Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes",[88],"2012-10","2008-08",[15],[3258,3272],"Digoxin",{"trials":3274,"activeCount":100},[],{"trials":3276,"activeCount":100},[],{"trials":3278,"activeCount":100},[],{"trials":3280,"activeCount":100},[],{"intervention":3272,"totalTrials":96,"cells":3282},{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3291,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3284,"activeCount":100},[],{"trials":3286,"activeCount":100},[3287],{"nctId":3265,"briefTitle":3266,"status":252,"phases":3288,"primaryCompletion":3268,"completion":3268,"start":3269,"enrollment":29,"conditions":3289,"interventions":3290},[88],[15],[3258,3272],{"trials":3292,"activeCount":100},[],{"trials":3294,"activeCount":100},[],{"trials":3296,"activeCount":100},[],{"trials":3298,"activeCount":100},[],{"intervention":3300,"totalTrials":96,"cells":3301},"Mifegyne",{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3314,"PHASE3":3316,"PHASE4":3318,"NA":3320},{"trials":3303,"activeCount":100},[],{"trials":3305,"activeCount":100},[3306],{"nctId":3307,"briefTitle":3308,"status":252,"phases":3309,"primaryCompletion":2950,"completion":2950,"start":3310,"enrollment":1967,"conditions":3311,"interventions":3313},"NCT00579475","The Effect of Mifepristone on Uterine Fibroids and Breast Tissue",[88],"2004-11",[3312],"Uterine Fibroids",[3300],{"trials":3315,"activeCount":100},[],{"trials":3317,"activeCount":100},[],{"trials":3319,"activeCount":100},[],{"trials":3321,"activeCount":100},[],{"intervention":3323,"totalTrials":96,"cells":3324},"Nω-hydroxy-nor-arginine",{"EARLY_PHASE1":3325,"PHASE1":3337,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3326,"activeCount":100},[3327],{"nctId":3328,"briefTitle":3329,"status":252,"phases":3330,"primaryCompletion":3331,"completion":3332,"start":2462,"enrollment":24,"conditions":3333,"interventions":3336},"NCT05536934","Arginase Inhibition in Humans With Obesity",[87],"2021-09","2022-03",[3334,3335],"Obese","Endothelial Function",[3323],{"trials":3338,"activeCount":100},[],{"trials":3340,"activeCount":100},[],{"trials":3342,"activeCount":100},[],{"trials":3344,"activeCount":100},[],{"trials":3346,"activeCount":100},[],{"intervention":3230,"totalTrials":545,"cells":3348},{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3357,"PHASE3":3359,"PHASE4":3370,"NA":3372},{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[3353],{"nctId":3225,"briefTitle":3226,"status":252,"phases":3354,"primaryCompletion":1926,"completion":1002,"start":1318,"enrollment":1293,"conditions":3355,"interventions":3356},[88],[2072,1168],[3218,3230],{"trials":3358,"activeCount":100},[],{"trials":3360,"activeCount":100},[3361],{"nctId":3362,"briefTitle":3363,"status":252,"phases":3364,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":622,"conditions":3367,"interventions":3368},"NCT04057755","Botulinum Toxin A as a Treatment for Provoked Vestibulodynia",[90],"2019-06-15","2016-05-15",[624],[3369,3230],"botulinum toxin A",{"trials":3371,"activeCount":100},[],{"trials":3373,"activeCount":100},[3374],{"nctId":3375,"briefTitle":3376,"status":252,"phases":3377,"primaryCompletion":2842,"completion":2842,"start":3378,"enrollment":3379,"conditions":3380,"interventions":3382},"NCT06085963","Nasal Allergen Challenge Test as a Method to Detect Clinical Reactivity Against Birch Pollen",[92],"2023-02-01",89,[3381],"Allergic Rhinitis Due to Pollen",[3383,3384],"ITULAZAX 12 SQ-Bet","Nacl",{"intervention":3386,"totalTrials":194,"cells":3387},"Dose of tinzaparin or dalteparin",{"EARLY_PHASE1":3388,"PHASE1":3390,"PHASE2":3392,"PHASE3":3394,"PHASE4":3396,"NA":3398},{"trials":3389,"activeCount":100},[],{"trials":3391,"activeCount":100},[],{"trials":3393,"activeCount":100},[],{"trials":3395,"activeCount":100},[],{"trials":3397,"activeCount":100},[],{"trials":3399,"activeCount":100},[3400,3412],{"nctId":3401,"briefTitle":3402,"status":252,"phases":3403,"primaryCompletion":3404,"completion":3405,"start":3406,"enrollment":3407,"conditions":3408,"interventions":3411},"NCT04593654","Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients",[],"2020-08-15","2020-10-15","2020-03-01",257,[3409,3410],"Covid19","Thromboembolism",[3386],{"nctId":3413,"briefTitle":3414,"status":252,"phases":3415,"primaryCompletion":3416,"completion":3417,"start":3418,"enrollment":3419,"conditions":3420,"interventions":3423},"NCT04412304","Anticoagulant Therapy and 28-days Mortality in Critically Ill COVID-19 Patients",[],"2020-04-30","2020-05-28","2020-03-06",166,[3421,3422,2279],"Covid-19","Thromboembolic Events",[3424],"Dose of Tinzaparin or Dalteparin",{"intervention":3369,"totalTrials":194,"cells":3426},{"EARLY_PHASE1":3427,"PHASE1":3429,"PHASE2":3431,"PHASE3":3433,"PHASE4":3439,"NA":3441},{"trials":3428,"activeCount":100},[],{"trials":3430,"activeCount":100},[],{"trials":3432,"activeCount":100},[],{"trials":3434,"activeCount":100},[3435],{"nctId":3362,"briefTitle":3363,"status":252,"phases":3436,"primaryCompletion":3365,"completion":3365,"start":3366,"enrollment":622,"conditions":3437,"interventions":3438},[90],[624],[3369,3230],{"trials":3440,"activeCount":100},[],{"trials":3442,"activeCount":100},[3443],{"nctId":3444,"briefTitle":3445,"status":252,"phases":3446,"primaryCompletion":1318,"completion":3447,"start":3448,"enrollment":3449,"conditions":3450,"interventions":3452},"NCT01590693","Botulinum Toxin A for Idiopathic Toe-walking",[92],"2012-04","2005-11",52,[3451],"Idiopathic Toe-walking",[3453],"Botulinum toxin A",{"intervention":3455,"totalTrials":194,"cells":3456},"Endotoxin",{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3461,"PHASE3":3463,"PHASE4":3465,"NA":3467},{"trials":3458,"activeCount":100},[],{"trials":3460,"activeCount":100},[],{"trials":3462,"activeCount":100},[],{"trials":3464,"activeCount":100},[],{"trials":3466,"activeCount":100},[],{"trials":3468,"activeCount":100},[3469,3476],{"nctId":3470,"briefTitle":3471,"status":252,"phases":3472,"primaryCompletion":1228,"completion":1228,"start":1165,"enrollment":3449,"conditions":3473,"interventions":3475},"NCT03551184","Inflammation and Brain Function - Main Study",[92],[3474],"Sickness Behavior",[3455],{"nctId":3477,"briefTitle":3478,"status":252,"phases":3479,"primaryCompletion":1345,"completion":1345,"start":1344,"enrollment":3480,"conditions":3481,"interventions":3482},"NCT02529592","Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual Differences",[92],22,[3474],[3455],{"intervention":3484,"totalTrials":194,"cells":3485},"Rituximab",{"EARLY_PHASE1":3486,"PHASE1":3488,"PHASE2":3490,"PHASE3":3492,"PHASE4":3505,"NA":3507},{"trials":3487,"activeCount":100},[],{"trials":3489,"activeCount":100},[],{"trials":3491,"activeCount":100},[],{"trials":3493,"activeCount":100},[3494],{"nctId":3495,"briefTitle":3496,"status":568,"phases":3497,"primaryCompletion":3498,"completion":3499,"start":3500,"enrollment":3501,"conditions":3502,"interventions":3504},"NCT03979456","RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS",[90],"2024-12-20","2025-06-01","2018-07-04",200,[3503],"Multiple Sclerosis, Relapsing-Remitting",[3484],{"trials":3506,"activeCount":100},[],{"trials":3508,"activeCount":100},[3509],{"nctId":3510,"briefTitle":3511,"status":252,"phases":3512,"primaryCompletion":3513,"completion":3513,"start":3514,"enrollment":3515,"conditions":3516,"interventions":3518},"NCT03193866","COMparison Between All immunoTherapies for Multiple Sclerosis.",[],"2022-03-31","2017-06-02",3526,[3517],"Relapsing-remitting Multiple Sclerosis",[3484],{"intervention":3520,"totalTrials":194,"cells":3521},"Infliximab",{"EARLY_PHASE1":3522,"PHASE1":3524,"PHASE2":3526,"PHASE3":3528,"PHASE4":3537,"NA":3539},{"trials":3523,"activeCount":100},[],{"trials":3525,"activeCount":100},[],{"trials":3527,"activeCount":100},[],{"trials":3529,"activeCount":100},[3530],{"nctId":3531,"briefTitle":3532,"status":252,"phases":3533,"conditions":3534,"interventions":3536},"NCT00443222","Treatment With TNF Blockade, Infliximab, in Patients With Myositis",[89,90],[3535],"Refractory Myositis",[3520],{"trials":3538,"activeCount":100},[],{"trials":3540,"activeCount":100},[3541],{"nctId":3542,"briefTitle":3543,"status":252,"phases":3544,"primaryCompletion":3545,"completion":3545,"start":3546,"enrollment":3547,"conditions":3548,"interventions":3549},"NCT05051137","Real-World Emulation of the SWEFOT Trial",[],"2020-11-16","2006-01-12",509,[1087],[3520,3550],"Sulfasalazine + Hydroxychloroquine",{"intervention":3552,"totalTrials":96,"cells":3553},"Mucosal tissue sampling",{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3560,"PHASE4":3562,"NA":3564},{"trials":3555,"activeCount":100},[],{"trials":3557,"activeCount":100},[],{"trials":3559,"activeCount":100},[],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[3566],{"nctId":3567,"briefTitle":3568,"status":252,"phases":3569,"primaryCompletion":3570,"completion":3570,"start":3571,"enrollment":3572,"conditions":3573,"interventions":3575},"NCT03302715","The Association Between the Microbiological Environment in Colon and Colorectal Disease",[92],"2019-07-01","2016-12-01",1257,[3574],"Microbial Colonization and Colorectal Disease",[3552],{"intervention":3577,"totalTrials":96,"cells":3578},"Antihypertensive Agents",{"EARLY_PHASE1":3579,"PHASE1":3581,"PHASE2":3583,"PHASE3":3585,"PHASE4":3587,"NA":3589},{"trials":3580,"activeCount":100},[],{"trials":3582,"activeCount":100},[],{"trials":3584,"activeCount":100},[],{"trials":3586,"activeCount":100},[],{"trials":3588,"activeCount":100},[],{"trials":3590,"activeCount":100},[3591],{"nctId":3592,"briefTitle":3593,"status":568,"phases":3594,"primaryCompletion":3595,"completion":3596,"start":3406,"enrollment":3597,"conditions":3598,"interventions":3599},"NCT04426084","Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study",[],"2021-06-08","2023-12-31",22784,[2044],[3577,3600],"Statins",{"intervention":3600,"totalTrials":96,"cells":3602},{"EARLY_PHASE1":3603,"PHASE1":3605,"PHASE2":3607,"PHASE3":3609,"PHASE4":3611,"NA":3613},{"trials":3604,"activeCount":100},[],{"trials":3606,"activeCount":100},[],{"trials":3608,"activeCount":100},[],{"trials":3610,"activeCount":100},[],{"trials":3612,"activeCount":100},[],{"trials":3614,"activeCount":100},[3615],{"nctId":3592,"briefTitle":3593,"status":568,"phases":3616,"primaryCompletion":3595,"completion":3596,"start":3406,"enrollment":3597,"conditions":3617,"interventions":3618},[],[2044],[3577,3600],{"intervention":3620,"totalTrials":96,"cells":3621},"Intensified insulin treatment",{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3628,"PHASE4":3630,"NA":3632},{"trials":3623,"activeCount":100},[],{"trials":3625,"activeCount":100},[],{"trials":3627,"activeCount":100},[],{"trials":3629,"activeCount":100},[],{"trials":3631,"activeCount":100},[],{"trials":3633,"activeCount":100},[3634],{"nctId":3635,"briefTitle":3636,"status":252,"phases":3637,"primaryCompletion":3638,"completion":3639,"start":3640,"enrollment":3641,"conditions":3642,"interventions":3644},"NCT01957930","Intensive Insulin Treatment and Ischemic Foot Ulcer",[92],"2011-12","2013-06","1984-01",91,[3643],"Ischemic Foot Ulcer",[3620,3645],"Standard treatment",{"intervention":3645,"totalTrials":96,"cells":3647},{"EARLY_PHASE1":3648,"PHASE1":3650,"PHASE2":3652,"PHASE3":3654,"PHASE4":3656,"NA":3658},{"trials":3649,"activeCount":100},[],{"trials":3651,"activeCount":100},[],{"trials":3653,"activeCount":100},[],{"trials":3655,"activeCount":100},[],{"trials":3657,"activeCount":100},[],{"trials":3659,"activeCount":100},[3660],{"nctId":3635,"briefTitle":3636,"status":252,"phases":3661,"primaryCompletion":3638,"completion":3639,"start":3640,"enrollment":3641,"conditions":3662,"interventions":3663},[92],[3643],[3620,3645],{"intervention":3665,"totalTrials":96,"cells":3666},"pegylated interferon-alpha",{"EARLY_PHASE1":3667,"PHASE1":3669,"PHASE2":3671,"PHASE3":3673,"PHASE4":3675,"NA":3677},{"trials":3668,"activeCount":100},[],{"trials":3670,"activeCount":100},[],{"trials":3672,"activeCount":100},[],{"trials":3674,"activeCount":100},[],{"trials":3676,"activeCount":100},[],{"trials":3678,"activeCount":100},[3679],{"nctId":3680,"briefTitle":3681,"status":252,"phases":3682,"enrollment":1098,"conditions":3683,"interventions":3686},"NCT00909129","Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment",[92],[3684,3685],"Human Immunodeficiency Virus","Chronic Hepatitis C",[3665,3687],"ribavirin",{"intervention":3687,"totalTrials":96,"cells":3689},{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3696,"PHASE4":3698,"NA":3700},{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":100},[],{"trials":3697,"activeCount":100},[],{"trials":3699,"activeCount":100},[],{"trials":3701,"activeCount":100},[3702],{"nctId":3680,"briefTitle":3681,"status":252,"phases":3703,"enrollment":1098,"conditions":3704,"interventions":3705},[92],[3684,3685],[3665,3687],{"intervention":3707,"totalTrials":96,"cells":3708},"Mirabegron",{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3713,"PHASE3":3715,"PHASE4":3717,"NA":3719},{"trials":3710,"activeCount":100},[],{"trials":3712,"activeCount":100},[],{"trials":3714,"activeCount":100},[],{"trials":3716,"activeCount":100},[],{"trials":3718,"activeCount":100},[],{"trials":3720,"activeCount":100},[3721],{"nctId":3722,"briefTitle":3723,"status":252,"phases":3724,"primaryCompletion":1897,"completion":1897,"start":2695,"enrollment":3725,"conditions":3726,"interventions":3728},"NCT02622555","Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists",[],221,[3727],"Overactive Bladder",[3707],{"intervention":3730,"totalTrials":96,"cells":3731},"sodium zirconium cyclosilicate and healthy diet",{"EARLY_PHASE1":3732,"PHASE1":3734,"PHASE2":3736,"PHASE3":3738,"PHASE4":3740,"NA":3742},{"trials":3733,"activeCount":100},[],{"trials":3735,"activeCount":100},[],{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[],{"trials":3741,"activeCount":100},[],{"trials":3743,"activeCount":100},[3744],{"nctId":3745,"briefTitle":3746,"status":252,"phases":3747,"primaryCompletion":3748,"completion":3749,"start":3750,"enrollment":16,"conditions":3751,"interventions":3755},"NCT04207203","Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study",[92],"2023-04-01","2023-05-10","2020-11-03",[3752,3753,3754],"Chronic Kidney Disease stage4","Chronic Kidney Disease Stage 5","Hyperkalemia",[3730],{"intervention":3757,"totalTrials":96,"cells":3758},"Lipopolysaccharide",{"EARLY_PHASE1":3759,"PHASE1":3761,"PHASE2":3763,"PHASE3":3765,"PHASE4":3767,"NA":3769},{"trials":3760,"activeCount":100},[],{"trials":3762,"activeCount":100},[],{"trials":3764,"activeCount":100},[],{"trials":3766,"activeCount":100},[],{"trials":3768,"activeCount":100},[],{"trials":3770,"activeCount":100},[3771],{"nctId":3772,"briefTitle":3773,"status":252,"phases":3774,"primaryCompletion":3775,"completion":3775,"start":1794,"enrollment":3776,"conditions":3777,"interventions":3778},"NCT03551080","Inflammation and Brain Function - Pilot Study",[92],"2009-12",8,[3474],[3757],{"intervention":3780,"totalTrials":96,"cells":3781},"Calcium hydroxide",{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3783,"activeCount":100},[],{"trials":3785,"activeCount":100},[],{"trials":3787,"activeCount":100},[],{"trials":3789,"activeCount":100},[],{"trials":3791,"activeCount":100},[],{"trials":3793,"activeCount":100},[3794],{"nctId":3795,"briefTitle":3796,"status":568,"phases":3797,"primaryCompletion":3798,"completion":3798,"start":3799,"enrollment":3800,"conditions":3801,"interventions":3803},"NCT04000854","Regenerative Treatment of Traumatized Immature Permanent Incisors With Pulp Necrosis",[92],"2023-12-19","2019-02-19",180,[3802],"Regenerative Endodontics in Traumatized Immature Teeth",[3780],{"intervention":3805,"totalTrials":96,"cells":3806},"STA 4783",{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3811,"PHASE3":3813,"PHASE4":3815,"NA":3817},{"trials":3808,"activeCount":100},[],{"trials":3810,"activeCount":100},[],{"trials":3812,"activeCount":100},[],{"trials":3814,"activeCount":100},[],{"trials":3816,"activeCount":100},[],{"trials":3818,"activeCount":100},[3819],{"nctId":3820,"briefTitle":3821,"status":252,"phases":3822,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":3825,"conditions":3826,"interventions":3828},"NCT06635252","Statins, Cholesterol and Cognitive Decline in Alzheimer's",[],"2025-03-01","2025-01-01",2000,[3827,3600],"Alzheimer Dementia",[3805],{"intervention":3550,"totalTrials":96,"cells":3830},{"EARLY_PHASE1":3831,"PHASE1":3833,"PHASE2":3835,"PHASE3":3837,"PHASE4":3839,"NA":3841},{"trials":3832,"activeCount":100},[],{"trials":3834,"activeCount":100},[],{"trials":3836,"activeCount":100},[],{"trials":3838,"activeCount":100},[],{"trials":3840,"activeCount":100},[],{"trials":3842,"activeCount":100},[3843],{"nctId":3542,"briefTitle":3543,"status":252,"phases":3844,"primaryCompletion":3545,"completion":3545,"start":3546,"enrollment":3547,"conditions":3845,"interventions":3846},[],[1087],[3520,3550],{"intervention":3848,"totalTrials":96,"cells":3849},"Laxabon",{"EARLY_PHASE1":3850,"PHASE1":3852,"PHASE2":3854,"PHASE3":3856,"PHASE4":3858,"NA":3860},{"trials":3851,"activeCount":100},[],{"trials":3853,"activeCount":100},[],{"trials":3855,"activeCount":100},[],{"trials":3857,"activeCount":100},[],{"trials":3859,"activeCount":100},[],{"trials":3861,"activeCount":100},[3862],{"nctId":3863,"briefTitle":3864,"status":1457,"phases":3865,"primaryCompletion":1794,"completion":1794,"start":3866,"enrollment":3867,"conditions":3868,"interventions":3871},"NCT00675324","Bowel Preparation Before Colonoscopy",[92],"2008-04",47,[3869,3870],"Colonoscopy","Bowel Preparation",[3848],{"intervention":3873,"totalTrials":96,"cells":3874},"Intensive insulin treatment",{"EARLY_PHASE1":3875,"PHASE1":3877,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3876,"activeCount":100},[],{"trials":3878,"activeCount":100},[],{"trials":3880,"activeCount":100},[],{"trials":3882,"activeCount":100},[],{"trials":3884,"activeCount":100},[],{"trials":3886,"activeCount":100},[3887],{"nctId":3888,"briefTitle":3889,"status":252,"phases":3890,"primaryCompletion":3638,"completion":3638,"start":3891,"enrollment":3892,"conditions":3893,"interventions":3896},"NCT02138006","Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes",[92],"1982-09",102,[3894,21,3895],"Coronary Heart Disease","Renal Failure",[3873,3897],"Standard insulin treatment",{"intervention":3897,"totalTrials":96,"cells":3899},{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3906,"PHASE4":3908,"NA":3910},{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[],{"trials":3905,"activeCount":100},[],{"trials":3907,"activeCount":100},[],{"trials":3909,"activeCount":100},[],{"trials":3911,"activeCount":100},[3912],{"nctId":3888,"briefTitle":3889,"status":252,"phases":3913,"primaryCompletion":3638,"completion":3638,"start":3891,"enrollment":3892,"conditions":3914,"interventions":3915},[92],[3894,21,3895],[3873,3897],{"intervention":3917,"totalTrials":96,"cells":3918},"Sevelamer",{"EARLY_PHASE1":3919,"PHASE1":3921,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3920,"activeCount":100},[],{"trials":3922,"activeCount":100},[],{"trials":3924,"activeCount":100},[],{"trials":3926,"activeCount":100},[],{"trials":3928,"activeCount":100},[],{"trials":3930,"activeCount":100},[3931],{"nctId":3932,"briefTitle":3933,"status":218,"phases":3934,"primaryCompletion":3935,"completion":3935,"start":1056,"enrollment":100,"conditions":3936,"interventions":3940},"NCT00837655","Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)",[92],"2011-06",[3937,3938,560,3939],"Kidney Failure, Chronic","End-Stage Renal Disease","Hyperphosphatemia",[3917,3941],"Calcium carbonate",{"intervention":3941,"totalTrials":96,"cells":3943},{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3950,"PHASE4":3952,"NA":3954},{"trials":3945,"activeCount":100},[],{"trials":3947,"activeCount":100},[],{"trials":3949,"activeCount":100},[],{"trials":3951,"activeCount":100},[],{"trials":3953,"activeCount":100},[],{"trials":3955,"activeCount":100},[3956],{"nctId":3932,"briefTitle":3933,"status":218,"phases":3957,"primaryCompletion":3935,"completion":3935,"start":1056,"enrollment":100,"conditions":3958,"interventions":3959},[92],[3937,3938,560,3939],[3917,3941],{"intervention":3961,"totalTrials":96,"cells":3962},"GLP-1",{"EARLY_PHASE1":3963,"PHASE1":3965,"PHASE2":3967,"PHASE3":3969,"PHASE4":3971,"NA":3973},{"trials":3964,"activeCount":100},[],{"trials":3966,"activeCount":100},[],{"trials":3968,"activeCount":100},[],{"trials":3970,"activeCount":100},[],{"trials":3972,"activeCount":100},[],{"trials":3974,"activeCount":100},[3975],{"nctId":3976,"briefTitle":3977,"status":252,"phases":3978,"primaryCompletion":1000,"completion":3979,"start":3980,"enrollment":3981,"conditions":3982,"interventions":3984},"NCT06913881","Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes",[],"2025-01-31","2010-01-01",92100,[3983],"Type 2 Diabetes Mellitus (T2DM)",[3961],{"intervention":3986,"totalTrials":96,"cells":3987},"Fluid bolus",{"EARLY_PHASE1":3988,"PHASE1":3990,"PHASE2":3992,"PHASE3":3994,"PHASE4":3996,"NA":3998},{"trials":3989,"activeCount":100},[],{"trials":3991,"activeCount":100},[],{"trials":3993,"activeCount":100},[],{"trials":3995,"activeCount":100},[],{"trials":3997,"activeCount":100},[],{"trials":3999,"activeCount":100},[4000],{"nctId":4001,"briefTitle":4002,"status":218,"phases":4003,"primaryCompletion":4004,"completion":4004,"start":4005,"enrollment":100,"conditions":4006,"interventions":4011},"NCT04576806","Physiological Effects of 38°C vs. 22°C Fluid Therapy in Critically Ill Patients",[92],"2021-10-30","2021-04-30",[4007,4008,4009,4010],"Critical Illness","Sepsis","Fluid Overload","Hemodynamic Instability",[3986],{"intervention":4013,"totalTrials":96,"cells":4014},"Intravenous thrombolysis by alteplase",{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4021,"PHASE4":4023,"NA":4025},{"trials":4016,"activeCount":100},[],{"trials":4018,"activeCount":100},[],{"trials":4020,"activeCount":100},[],{"trials":4022,"activeCount":100},[],{"trials":4024,"activeCount":100},[],{"trials":4026,"activeCount":100},[4027],{"nctId":4028,"briefTitle":4029,"status":252,"phases":4030,"primaryCompletion":255,"completion":255,"start":2694,"enrollment":4031,"conditions":4032,"interventions":4034},"NCT02326428","SITS (Safe Implementation of Treatments in Stroke) Open Artery by Thrombectomy in Acute Occlusive Stroke Study",[92],341,[4033],"Ischemic Stroke",[4013],{"intervention":4036,"totalTrials":96,"cells":4037},"Single corticosteroid inhalers and Singulair",{"EARLY_PHASE1":4038,"PHASE1":4040,"PHASE2":4042,"PHASE3":4044,"PHASE4":4046,"NA":4048},{"trials":4039,"activeCount":100},[],{"trials":4041,"activeCount":100},[],{"trials":4043,"activeCount":100},[],{"trials":4045,"activeCount":100},[],{"trials":4047,"activeCount":100},[],{"trials":4049,"activeCount":100},[4050],{"nctId":4051,"briefTitle":4052,"status":252,"phases":4053,"primaryCompletion":1795,"completion":1795,"start":4054,"enrollment":4055,"conditions":4056,"interventions":4058},"NCT00421018","Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)",[92],"2006-11",187,[4057],"Allergic Asthma",[4036],{"intervention":4060,"totalTrials":96,"cells":4061},"Exendin 9-39",{"EARLY_PHASE1":4062,"PHASE1":4064,"PHASE2":4066,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4063,"activeCount":100},[],{"trials":4065,"activeCount":100},[],{"trials":4067,"activeCount":100},[],{"trials":4069,"activeCount":100},[],{"trials":4071,"activeCount":100},[],{"trials":4073,"activeCount":100},[4074],{"nctId":4075,"briefTitle":4076,"status":252,"phases":4077,"primaryCompletion":254,"completion":255,"start":1880,"enrollment":2578,"conditions":4078,"interventions":4080},"NCT02746757","Glucagon Like Peptide-1 in Remote Ischemic Conditioning",[92],[4079],"Healthy Volunteers",[4060],{"intervention":4082,"totalTrials":96,"cells":4083},"The effect of LMWH",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4088,"PHASE3":4090,"PHASE4":4092,"NA":4094},{"trials":4085,"activeCount":100},[],{"trials":4087,"activeCount":100},[],{"trials":4089,"activeCount":100},[],{"trials":4091,"activeCount":100},[],{"trials":4093,"activeCount":100},[],{"trials":4095,"activeCount":100},[4096],{"nctId":4097,"briefTitle":4098,"status":252,"phases":4099,"primaryCompletion":4100,"completion":4101,"start":3406,"enrollment":4102,"conditions":4103,"interventions":4104},"NCT05256524","Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin?",[],"2021-05-31","2021-08-29",1520,[3409,3410,2279],[4082],{"intervention":4106,"totalTrials":96,"cells":4107},"Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4109,"activeCount":100},[],{"trials":4111,"activeCount":100},[],{"trials":4113,"activeCount":100},[],{"trials":4115,"activeCount":100},[],{"trials":4117,"activeCount":100},[],{"trials":4119,"activeCount":100},[4120],{"nctId":4121,"briefTitle":4122,"status":252,"phases":4123,"primaryCompletion":4124,"completion":4124,"start":4125,"enrollment":672,"conditions":4126,"interventions":4128},"NCT03375775","Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children",[92],"2022-01-31","2017-05-01",[1882,4127,948],"Conjunctivitis, Allergic",[4106],{"intervention":4130,"totalTrials":96,"cells":4131},"Endocrine therapy",{"EARLY_PHASE1":4132,"PHASE1":4134,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4142},{"trials":4133,"activeCount":100},[],{"trials":4135,"activeCount":100},[],{"trials":4137,"activeCount":100},[],{"trials":4139,"activeCount":100},[],{"trials":4141,"activeCount":100},[],{"trials":4143,"activeCount":100},[4144],{"nctId":4145,"briefTitle":4146,"status":252,"phases":4147,"primaryCompletion":4148,"completion":4149,"start":4150,"enrollment":4151,"conditions":4152,"interventions":4153},"NCT03390608","Prognostic and Predictive Factors for Small Breast Tumors",[],"2014-12-31","2016-07-30","1977-01-01",35002,[285],[4130,4154,4155],"Herceptin","Chemotherapy",{"intervention":4154,"totalTrials":96,"cells":4157},{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4159,"activeCount":100},[],{"trials":4161,"activeCount":100},[],{"trials":4163,"activeCount":100},[],{"trials":4165,"activeCount":100},[],{"trials":4167,"activeCount":100},[],{"trials":4169,"activeCount":100},[4170],{"nctId":4145,"briefTitle":4146,"status":252,"phases":4171,"primaryCompletion":4148,"completion":4149,"start":4150,"enrollment":4151,"conditions":4172,"interventions":4173},[],[285],[4130,4154,4155],{"intervention":4155,"totalTrials":96,"cells":4175},{"EARLY_PHASE1":4176,"PHASE1":4178,"PHASE2":4180,"PHASE3":4182,"PHASE4":4184,"NA":4186},{"trials":4177,"activeCount":100},[],{"trials":4179,"activeCount":100},[],{"trials":4181,"activeCount":100},[],{"trials":4183,"activeCount":100},[],{"trials":4185,"activeCount":100},[],{"trials":4187,"activeCount":100},[4188],{"nctId":4145,"briefTitle":4146,"status":252,"phases":4189,"primaryCompletion":4148,"completion":4149,"start":4150,"enrollment":4151,"conditions":4190,"interventions":4191},[],[285],[4130,4154,4155],{"intervention":4193,"totalTrials":96,"cells":4194},"DNA exome sequencing of tumor and blood",{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4199,"PHASE3":4201,"PHASE4":4203,"NA":4205},{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[],{"trials":4200,"activeCount":100},[],{"trials":4202,"activeCount":100},[],{"trials":4204,"activeCount":100},[],{"trials":4206,"activeCount":100},[4207],{"nctId":4208,"briefTitle":4209,"status":568,"phases":4210,"primaryCompletion":4211,"completion":4212,"start":4213,"enrollment":19,"conditions":4214,"interventions":4216},"NCT06094985","Prognostic Markers for a Better Follow-up in Head and Neck Cancer.",[],"2024-05-31","2026-05-31","2014-02-12",[4215],"Head and Neck Cancer",[4193],{"intervention":4218,"totalTrials":96,"cells":4219},"Proton pump inhibitor",{"EARLY_PHASE1":4220,"PHASE1":4222,"PHASE2":4224,"PHASE3":4226,"PHASE4":4228,"NA":4230},{"trials":4221,"activeCount":100},[],{"trials":4223,"activeCount":100},[],{"trials":4225,"activeCount":100},[],{"trials":4227,"activeCount":100},[],{"trials":4229,"activeCount":100},[],{"trials":4231,"activeCount":100},[4232],{"nctId":4233,"briefTitle":4234,"status":252,"phases":4235,"primaryCompletion":4236,"completion":4236,"start":2301,"enrollment":4237,"conditions":4238,"interventions":4242},"NCT05688761","Nordic Gastric and Esophageal Tumor Study",[],"2022-12-28",900000,[4239,4240,4241],"Cancer of Stomach","Cancer of the Esophagus","Drug Use",[4218],{"intervention":4244,"totalTrials":96,"cells":4245},"Ringer's Acetate",{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4252,"PHASE4":4254,"NA":4256},{"trials":4247,"activeCount":100},[],{"trials":4249,"activeCount":100},[],{"trials":4251,"activeCount":100},[],{"trials":4253,"activeCount":100},[],{"trials":4255,"activeCount":100},[],{"trials":4257,"activeCount":100},[4258],{"nctId":4259,"briefTitle":4260,"status":252,"phases":4261,"primaryCompletion":4262,"completion":4262,"start":4263,"enrollment":4264,"conditions":4265,"interventions":4268},"NCT03209271","Hemodynamic Effects of Cold Versus Warm Fluid Bolus",[92],"2017-05-27","2017-02-03",21,[4266,4267],"Temperature Change, Body","Hypovolemia",[4244,4244],{"intervention":4270,"totalTrials":96,"cells":4271},"Risedronate",{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4276,"PHASE3":4278,"PHASE4":4280,"NA":4282},{"trials":4273,"activeCount":100},[],{"trials":4275,"activeCount":100},[],{"trials":4277,"activeCount":100},[],{"trials":4279,"activeCount":100},[],{"trials":4281,"activeCount":100},[],{"trials":4283,"activeCount":100},[4284],{"nctId":4285,"briefTitle":4286,"status":252,"phases":4287,"primaryCompletion":4288,"completion":4288,"start":4289,"enrollment":4290,"conditions":4291,"interventions":4293},"NCT01950169","Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture",[92],"2009-05","2004-12",79,[4292],"Hip Fracture",[4270],{"intervention":4295,"totalTrials":96,"cells":4296},"adalimumab",{"EARLY_PHASE1":4297,"PHASE1":4299,"PHASE2":4301,"PHASE3":4303,"PHASE4":4305,"NA":4307},{"trials":4298,"activeCount":100},[],{"trials":4300,"activeCount":100},[],{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"trials":4308,"activeCount":100},[4309],{"nctId":4310,"briefTitle":4311,"status":252,"phases":4312,"primaryCompletion":4313,"completion":4313,"start":1165,"enrollment":4314,"conditions":4315,"interventions":4318},"NCT01197144","Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab",[92],"2016-11-28",70,[4316,1464,4317],"Arthritis, Rheumatoid","Fatigue",[4295],{"intervention":4320,"totalTrials":96,"cells":4321},"Initiation of specific medications",{"EARLY_PHASE1":4322,"PHASE1":4324,"PHASE2":4326,"PHASE3":4328,"PHASE4":4330,"NA":4332},{"trials":4323,"activeCount":100},[],{"trials":4325,"activeCount":100},[],{"trials":4327,"activeCount":100},[],{"trials":4329,"activeCount":100},[],{"trials":4331,"activeCount":100},[],{"trials":4333,"activeCount":100},[4334],{"nctId":4335,"briefTitle":4336,"status":252,"phases":4337,"primaryCompletion":1000,"completion":966,"start":4338,"enrollment":4339,"conditions":4340,"interventions":4344},"NCT06239129","The Stockholm CREAtinine Measurements Project",[],"2006-01-01",3200000,[4341,4342,1491,4343,1348],"Chronic Kidney Diseases","Acute Kidney Injury","Cardiovascular Diseases",[4320],{"intervention":4346,"totalTrials":96,"cells":4347},"Anticoagulants",{"EARLY_PHASE1":4348,"PHASE1":4350,"PHASE2":4352,"PHASE3":4354,"PHASE4":4356,"NA":4358},{"trials":4349,"activeCount":100},[],{"trials":4351,"activeCount":100},[],{"trials":4353,"activeCount":100},[],{"trials":4355,"activeCount":100},[],{"trials":4357,"activeCount":100},[],{"trials":4359,"activeCount":100},[4360],{"nctId":4361,"briefTitle":4362,"status":252,"phases":4363,"primaryCompletion":4364,"completion":4365,"start":4366,"enrollment":4367,"conditions":4368,"interventions":4371},"NCT03828162","Atrial Fibrillation: Risk and Benefits of Anti-coagulation in the Elderly",[],"2017-12-31","2018-12-31","2010-11-01",2943,[4369,28,4370],"Anticoagulants Causing Adverse Effects in Therapeutic Use","Frail Elderly Syndrome",[4346],{"intervention":3383,"totalTrials":96,"cells":4373},{"EARLY_PHASE1":4374,"PHASE1":4376,"PHASE2":4378,"PHASE3":4380,"PHASE4":4382,"NA":4384},{"trials":4375,"activeCount":100},[],{"trials":4377,"activeCount":100},[],{"trials":4379,"activeCount":100},[],{"trials":4381,"activeCount":100},[],{"trials":4383,"activeCount":100},[],{"trials":4385,"activeCount":100},[4386],{"nctId":3375,"briefTitle":3376,"status":252,"phases":4387,"primaryCompletion":2842,"completion":2842,"start":3378,"enrollment":3379,"conditions":4388,"interventions":4389},[92],[3381],[3383,3384],{"intervention":4391,"totalTrials":96,"cells":4392},"Valganciclovir",{"EARLY_PHASE1":4393,"PHASE1":4395,"PHASE2":4397,"PHASE3":4399,"PHASE4":4401,"NA":4403},{"trials":4394,"activeCount":100},[],{"trials":4396,"activeCount":100},[],{"trials":4398,"activeCount":100},[],{"trials":4400,"activeCount":100},[],{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":100},[4405],{"nctId":4406,"briefTitle":4407,"status":252,"phases":4408,"primaryCompletion":1991,"completion":1991,"start":4409,"enrollment":2887,"conditions":4410,"interventions":4413},"NCT00400322","Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection",[92],"2006-08",[4411,4412],"Glioblastoma Multiforme","Cytomegalovirus Infection",[4391],{"intervention":4415,"totalTrials":96,"cells":4416},"methylphenidate medication",{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4423,"PHASE4":4425,"NA":4427},{"trials":4418,"activeCount":100},[],{"trials":4420,"activeCount":100},[],{"trials":4422,"activeCount":100},[],{"trials":4424,"activeCount":100},[],{"trials":4426,"activeCount":100},[],{"trials":4428,"activeCount":100},[4429],{"nctId":4430,"briefTitle":4431,"status":252,"phases":4432,"primaryCompletion":4433,"completion":4434,"start":4435,"enrollment":4436,"conditions":4437,"interventions":4439},"NCT02136147","ADHD Medication and Predictors of Treatment Outcome",[],"2021-07","2022-06","2015-06",632,[4438],"Attention Deficit Disorder With Hyperactivity (ADHD)",[4415,4440,4441,4442],"atomoxetine medication","lisdexamphetamine medication","guanfacine medication",{"intervention":4440,"totalTrials":96,"cells":4444},{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4449,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4446,"activeCount":100},[],{"trials":4448,"activeCount":100},[],{"trials":4450,"activeCount":100},[],{"trials":4452,"activeCount":100},[],{"trials":4454,"activeCount":100},[],{"trials":4456,"activeCount":100},[4457],{"nctId":4430,"briefTitle":4431,"status":252,"phases":4458,"primaryCompletion":4433,"completion":4434,"start":4435,"enrollment":4436,"conditions":4459,"interventions":4460},[],[4438],[4415,4440,4441,4442],{"intervention":4441,"totalTrials":96,"cells":4462},{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4469,"PHASE4":4471,"NA":4473},{"trials":4464,"activeCount":100},[],{"trials":4466,"activeCount":100},[],{"trials":4468,"activeCount":100},[],{"trials":4470,"activeCount":100},[],{"trials":4472,"activeCount":100},[],{"trials":4474,"activeCount":100},[4475],{"nctId":4430,"briefTitle":4431,"status":252,"phases":4476,"primaryCompletion":4433,"completion":4434,"start":4435,"enrollment":4436,"conditions":4477,"interventions":4478},[],[4438],[4415,4440,4441,4442],{"intervention":4442,"totalTrials":96,"cells":4480},{"EARLY_PHASE1":4481,"PHASE1":4483,"PHASE2":4485,"PHASE3":4487,"PHASE4":4489,"NA":4491},{"trials":4482,"activeCount":100},[],{"trials":4484,"activeCount":100},[],{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":100},[],{"trials":4492,"activeCount":100},[4493],{"nctId":4430,"briefTitle":4431,"status":252,"phases":4494,"primaryCompletion":4433,"completion":4434,"start":4435,"enrollment":4436,"conditions":4495,"interventions":4496},[],[4438],[4415,4440,4441,4442],{"intervention":4498,"totalTrials":96,"cells":4499},"Contrast Enhanced Mammography",{"EARLY_PHASE1":4500,"PHASE1":4502,"PHASE2":4504,"PHASE3":4506,"PHASE4":4508,"NA":4510},{"trials":4501,"activeCount":100},[],{"trials":4503,"activeCount":100},[],{"trials":4505,"activeCount":100},[],{"trials":4507,"activeCount":100},[],{"trials":4509,"activeCount":100},[],{"trials":4511,"activeCount":100},[4512],{"nctId":4513,"briefTitle":4514,"status":568,"phases":4515,"primaryCompletion":4516,"completion":4211,"start":4517,"enrollment":4518,"conditions":4519,"interventions":4520},"NCT04579107","KARMA Kontrast Evaluating Contrast Enhanced Mammography in Early Detection of Breast Cancer",[92],"2024-04-01","2021-10-01",420,[285],[4498],{"intervention":4522,"totalTrials":96,"cells":4523},"Laxabon®",{"EARLY_PHASE1":4524,"PHASE1":4526,"PHASE2":4528,"PHASE3":4530,"PHASE4":4532,"NA":4534},{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":100},[],{"trials":4529,"activeCount":100},[],{"trials":4531,"activeCount":100},[],{"trials":4533,"activeCount":100},[],{"trials":4535,"activeCount":100},[4536],{"nctId":4537,"briefTitle":4538,"status":252,"phases":4539,"primaryCompletion":4540,"completion":4540,"start":4541,"enrollment":4542,"conditions":4543,"interventions":4545},"NCT00687570","Bowel Preparation Before Rectal Cancer Surgery",[92],"2014-07","2008-07",32,[4544],"Rectal Cancer",[4522]]